<SEC-DOCUMENT>0001551152-21-000013.txt : 20210430
<SEC-HEADER>0001551152-21-000013.hdr.sgml : 20210430
<ACCEPTANCE-DATETIME>20210430074456
ACCESSION NUMBER:		0001551152-21-000013
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20210430
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210430
DATE AS OF CHANGE:		20210430

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AbbVie Inc.
		CENTRAL INDEX KEY:			0001551152
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				320375147
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35565
		FILM NUMBER:		21873769

	BUSINESS ADDRESS:	
		STREET 1:		1 NORTH WAUKEGAN ROAD
		CITY:			NORTH CHICAGO
		STATE:			IL
		ZIP:			60064
		BUSINESS PHONE:		(847) 932-7900

	MAIL ADDRESS:	
		STREET 1:		1 NORTH WAUKEGAN ROAD
		CITY:			NORTH CHICAGO
		STATE:			IL
		ZIP:			60064
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>abbv-20210430.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:3e7f0185-a9a1-4b61-815f-c61e42d62e69,g:da78bc11-9ed2-4b3e-b8cf-99a0859a3322,d:8aeb700ba8d3432bb188cb161c1da14f--><html xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:abbv="http://www.abbvie.com/20210430" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>abbv-20210430</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i372845ab48f94e268be1959a2195352e_D20210430-20210430" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl80L2ZyYWc6NTQ2NDhmYmIwYzNlNDIzM2E1OWQ3OWYwYWVhMjBjNDAvdGFibGU6MWFmMWUxYWEwYzg4NDYyMDg2YzEzNjJiNTljMDQyNjcvdGFibGVyYW5nZToxYWYxZTFhYTBjODg0NjIwODZjMTM2MmI1OWMwNDI2N18xLTEtMS0xLTA_d99a2d43-9af8-4b1a-bf41-0f16c4482780">0001551152</ix:nonNumeric><ix:nonNumeric contextRef="i372845ab48f94e268be1959a2195352e_D20210430-20210430" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl80L2ZyYWc6NTQ2NDhmYmIwYzNlNDIzM2E1OWQ3OWYwYWVhMjBjNDAvdGFibGU6MWFmMWUxYWEwYzg4NDYyMDg2YzEzNjJiNTljMDQyNjcvdGFibGVyYW5nZToxYWYxZTFhYTBjODg0NjIwODZjMTM2MmI1OWMwNDI2N18yLTEtMS0xLTA_a36a37f6-d5b7-4b07-999b-d7829b67244d">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="abbv-20210430.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i372845ab48f94e268be1959a2195352e_D20210430-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-30</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e3151e7fbc24bb8ab5b9d54d0894a99_D20210430-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XCHI</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-30</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10cf4baaf38643babf7c0c0f6190fb60_D20210430-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNYS</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-30</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iacc41bc3fbb54680a429dc8cb29689bb_D20210430-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abbv:Sec0500SeniorNotesDue2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNYS</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-30</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iacaeb3ad67e84bcab6f0ff402ffc8bdb_D20210430-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNYS</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abbv:Sec1500SeniorNotesDue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-30</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87f971760f124ed79664442df3b25e34_D20210430-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abbv:Sec1.375SeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNYS</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-30</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib272ba06fa0d4b20b8126cadf25c8d44_D20210430-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNYS</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abbv:Sec1250SeniorNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-30</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia74871cf5e6446fe98daf5c758cc9155_D20210430-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNYS</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abbv:Sec0.750SeniorNotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-30</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7c02690c2a54e689107d2d34c8a565d_D20210430-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNYS</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abbv:Sec2.125SeniorNotesdue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-30</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29032be1176d413e92e42e8adbbab24d_D20210430-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abbv:Sec2625SeniorNotesDue2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNYS</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-30</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc45b489215749e7960282bf6274a10f_D20210430-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNYS</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abbv:Sec2125SeniorNotesDue2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-30</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ed7fd5ee92346588519bb73fa7ddd03_D20210430-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNYS</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abbv:Sec1.250SeniorNotesdue2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-30</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i8aeb700ba8d3432bb188cb161c1da14f_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;_____________________________________________________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM&#160;<ix:nonNumeric contextRef="i372845ab48f94e268be1959a2195352e_D20210430-20210430" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl8xL2ZyYWc6OGE0MTU3ZTViN2M5NDcxNmIyNjJhODFjOTE4Y2IzNDIvdGV4dHJlZ2lvbjo4YTQxNTdlNWI3Yzk0NzE2YjI2MmE4MWM5MThjYjM0Ml8xODQ4_070e1a23-d35e-4554-84e9-3c18b19fc07e">8-K</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160; </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section&#160;13 or 15(d)&#160;of the</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Securities Exchange Act of 1934</span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="i372845ab48f94e268be1959a2195352e_D20210430-20210430" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl8xL2ZyYWc6OGE0MTU3ZTViN2M5NDcxNmIyNjJhODFjOTE4Y2IzNDIvdGV4dHJlZ2lvbjo4YTQxNTdlNWI3Yzk0NzE2YjI2MmE4MWM5MThjYjM0Ml8yODU_ecaec868-534b-4b0c-b19f-4d1ea4805929">April 30, 2021</ix:nonNumeric> </span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i372845ab48f94e268be1959a2195352e_D20210430-20210430" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl8xL2ZyYWc6OGE0MTU3ZTViN2M5NDcxNmIyNjJhODFjOTE4Y2IzNDIvdGV4dHJlZ2lvbjo4YTQxNTdlNWI3Yzk0NzE2YjI2MmE4MWM5MThjYjM0Ml8xODUx_6c10018c-c119-459a-a550-3010630f7615">ABBVIE INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:29.793%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.413%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.939%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.413%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.942%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i372845ab48f94e268be1959a2195352e_D20210430-20210430" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl8xL2ZyYWc6OGE0MTU3ZTViN2M5NDcxNmIyNjJhODFjOTE4Y2IzNDIvdGFibGU6N2YyMzY0ZDQ2ODkyNDhhMGJlYjQ4M2VmNWNkYjI3NWQvdGFibGVyYW5nZTo3ZjIzNjRkNDY4OTI0OGEwYmViNDgzZWY1Y2RiMjc1ZF8wLTAtMS0xLTA_2c70bc84-6a91-4d03-8654-e74c4dbc9a64">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i372845ab48f94e268be1959a2195352e_D20210430-20210430" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl8xL2ZyYWc6OGE0MTU3ZTViN2M5NDcxNmIyNjJhODFjOTE4Y2IzNDIvdGFibGU6N2YyMzY0ZDQ2ODkyNDhhMGJlYjQ4M2VmNWNkYjI3NWQvdGFibGVyYW5nZTo3ZjIzNjRkNDY4OTI0OGEwYmViNDgzZWY1Y2RiMjc1ZF8wLTItMS0xLTA_3eae6238-bdf8-4a32-8451-eb7e7f9061a6">001-35565</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i372845ab48f94e268be1959a2195352e_D20210430-20210430" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl8xL2ZyYWc6OGE0MTU3ZTViN2M5NDcxNmIyNjJhODFjOTE4Y2IzNDIvdGFibGU6N2YyMzY0ZDQ2ODkyNDhhMGJlYjQ4M2VmNWNkYjI3NWQvdGFibGVyYW5nZTo3ZjIzNjRkNDY4OTI0OGEwYmViNDgzZWY1Y2RiMjc1ZF8wLTQtMS0xLTA_91610947-5155-4811-ad10-1a6b08d31cc2">32-0375147</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other Jurisdiction</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Commission File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(IRS Employer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">of Incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identification No.)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;_____________________________________________________</span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i372845ab48f94e268be1959a2195352e_D20210430-20210430" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl8xL2ZyYWc6OGE0MTU3ZTViN2M5NDcxNmIyNjJhODFjOTE4Y2IzNDIvdGV4dHJlZ2lvbjo4YTQxNTdlNWI3Yzk0NzE2YjI2MmE4MWM5MThjYjM0Ml8xODUw_787ef247-42bc-46e9-a154-bf58c79f159c">1 North Waukegan Road</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i372845ab48f94e268be1959a2195352e_D20210430-20210430" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl8xL2ZyYWc6OGE0MTU3ZTViN2M5NDcxNmIyNjJhODFjOTE4Y2IzNDIvdGV4dHJlZ2lvbjo4YTQxNTdlNWI3Yzk0NzE2YjI2MmE4MWM5MThjYjM0Ml8xODU1_e2a989f1-74b1-4e9c-bda0-26010d3a4ba6">North Chicago</ix:nonNumeric>,&#160;<ix:nonNumeric contextRef="i372845ab48f94e268be1959a2195352e_D20210430-20210430" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl8xL2ZyYWc6OGE0MTU3ZTViN2M5NDcxNmIyNjJhODFjOTE4Y2IzNDIvdGV4dHJlZ2lvbjo4YTQxNTdlNWI3Yzk0NzE2YjI2MmE4MWM5MThjYjM0Ml8xODQ0_3fafd611-c958-48ea-8858-6fb0e6974245">Illinois</ix:nonNumeric> <ix:nonNumeric contextRef="i372845ab48f94e268be1959a2195352e_D20210430-20210430" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl8xL2ZyYWc6OGE0MTU3ZTViN2M5NDcxNmIyNjJhODFjOTE4Y2IzNDIvdGV4dHJlZ2lvbjo4YTQxNTdlNWI3Yzk0NzE2YjI2MmE4MWM5MThjYjM0Ml8xODQ1_c359225a-337b-47c9-a7fb-1c651b3effd7">60064-6400</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Address of principal executive offices)(Zip Code)</span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160; </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Registrant&#8217;s telephone number, including area code:&#160; </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i372845ab48f94e268be1959a2195352e_D20210430-20210430" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl8xL2ZyYWc6OGE0MTU3ZTViN2M5NDcxNmIyNjJhODFjOTE4Y2IzNDIvdGV4dHJlZ2lvbjo4YTQxNTdlNWI3Yzk0NzE2YjI2MmE4MWM5MThjYjM0Ml8xODQ2_e63071bf-da37-423d-8c3c-61440df47ab7">847</ix:nonNumeric>) <ix:nonNumeric contextRef="i372845ab48f94e268be1959a2195352e_D20210430-20210430" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl8xL2ZyYWc6OGE0MTU3ZTViN2M5NDcxNmIyNjJhODFjOTE4Y2IzNDIvdGV4dHJlZ2lvbjo4YTQxNTdlNWI3Yzk0NzE2YjI2MmE4MWM5MThjYjM0Ml8xODU2_f850c349-a63d-4985-a919-c42e7cf3f5f9">932-7900</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i372845ab48f94e268be1959a2195352e_D20210430-20210430" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl8xL2ZyYWc6OGE0MTU3ZTViN2M5NDcxNmIyNjJhODFjOTE4Y2IzNDIvdGV4dHJlZ2lvbjo4YTQxNTdlNWI3Yzk0NzE2YjI2MmE4MWM5MThjYjM0Ml8xODQ5_ec233757-5deb-4319-af1e-c6be4480ef58">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:3pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i372845ab48f94e268be1959a2195352e_D20210430-20210430" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl8xL2ZyYWc6OGE0MTU3ZTViN2M5NDcxNmIyNjJhODFjOTE4Y2IzNDIvdGV4dHJlZ2lvbjo4YTQxNTdlNWI3Yzk0NzE2YjI2MmE4MWM5MThjYjM0Ml8xODUy_74dc11d1-e946-4ca3-9541-94f92116f772">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:3pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i372845ab48f94e268be1959a2195352e_D20210430-20210430" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl8xL2ZyYWc6OGE0MTU3ZTViN2M5NDcxNmIyNjJhODFjOTE4Y2IzNDIvdGV4dHJlZ2lvbjo4YTQxNTdlNWI3Yzk0NzE2YjI2MmE4MWM5MThjYjM0Ml8xODUz_cb215879-0c43-4202-bf8d-7e044e3ed0f5">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:3pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i372845ab48f94e268be1959a2195352e_D20210430-20210430" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl8xL2ZyYWc6OGE0MTU3ZTViN2M5NDcxNmIyNjJhODFjOTE4Y2IzNDIvdGV4dHJlZ2lvbjo4YTQxNTdlNWI3Yzk0NzE2YjI2MmE4MWM5MThjYjM0Ml8xODU0_3642f344-d344-437f-84ba-7bb5ca3ce316">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:3pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:29.975%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.714%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.975%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.714%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.922%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Title&#160;of&#160;each&#160;class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Trading&#160;Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2e3151e7fbc24bb8ab5b9d54d0894a99_D20210430-20210430" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl8xL2ZyYWc6OGE0MTU3ZTViN2M5NDcxNmIyNjJhODFjOTE4Y2IzNDIvdGFibGU6NWVmYmU4OTVmZDFmNDc4NTk3ODBjYmZjMjVlMTJkYTYvdGFibGVyYW5nZTo1ZWZiZTg5NWZkMWY0Nzg1OTc4MGNiZmMyNWUxMmRhNl8xLTAtMS0xLTA_4e7af9ce-dd3d-4f67-b75d-e9db26b893f9"><ix:nonNumeric contextRef="i10cf4baaf38643babf7c0c0f6190fb60_D20210430-20210430" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl8xL2ZyYWc6OGE0MTU3ZTViN2M5NDcxNmIyNjJhODFjOTE4Y2IzNDIvdGFibGU6NWVmYmU4OTVmZDFmNDc4NTk3ODBjYmZjMjVlMTJkYTYvdGFibGVyYW5nZTo1ZWZiZTg5NWZkMWY0Nzg1OTc4MGNiZmMyNWUxMmRhNl8xLTAtMS0xLTA_eb4d8039-376a-43f6-8c53-6df8f8f0a8a1">Common Stock, $0.01 Par Value</ix:nonNumeric></ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2e3151e7fbc24bb8ab5b9d54d0894a99_D20210430-20210430" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl8xL2ZyYWc6OGE0MTU3ZTViN2M5NDcxNmIyNjJhODFjOTE4Y2IzNDIvdGFibGU6NWVmYmU4OTVmZDFmNDc4NTk3ODBjYmZjMjVlMTJkYTYvdGFibGVyYW5nZTo1ZWZiZTg5NWZkMWY0Nzg1OTc4MGNiZmMyNWUxMmRhNl8xLTItMS0xLTA_5bcac279-3c62-4917-8bef-2659d4aa937c"><ix:nonNumeric contextRef="i10cf4baaf38643babf7c0c0f6190fb60_D20210430-20210430" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl8xL2ZyYWc6OGE0MTU3ZTViN2M5NDcxNmIyNjJhODFjOTE4Y2IzNDIvdGFibGU6NWVmYmU4OTVmZDFmNDc4NTk3ODBjYmZjMjVlMTJkYTYvdGFibGVyYW5nZTo1ZWZiZTg5NWZkMWY0Nzg1OTc4MGNiZmMyNWUxMmRhNl8xLTItMS0xLTA_6b350c0d-b591-4527-9aa1-fdbf615c5dd0">ABBV</ix:nonNumeric></ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i10cf4baaf38643babf7c0c0f6190fb60_D20210430-20210430" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl8xL2ZyYWc6OGE0MTU3ZTViN2M5NDcxNmIyNjJhODFjOTE4Y2IzNDIvdGFibGU6NWVmYmU4OTVmZDFmNDc4NTk3ODBjYmZjMjVlMTJkYTYvdGFibGVyYW5nZTo1ZWZiZTg5NWZkMWY0Nzg1OTc4MGNiZmMyNWUxMmRhNl8xLTQtMS0xLTA_1dc2d84a-4c44-43bb-bea2-5c2a75e7efd2">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2e3151e7fbc24bb8ab5b9d54d0894a99_D20210430-20210430" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl8xL2ZyYWc6OGE0MTU3ZTViN2M5NDcxNmIyNjJhODFjOTE4Y2IzNDIvdGFibGU6NWVmYmU4OTVmZDFmNDc4NTk3ODBjYmZjMjVlMTJkYTYvdGFibGVyYW5nZTo1ZWZiZTg5NWZkMWY0Nzg1OTc4MGNiZmMyNWUxMmRhNl8yLTQtMS0xLTA_217ab4c0-f15e-498e-8bb0-6cfaa7990a43">Chicago Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iacc41bc3fbb54680a429dc8cb29689bb_D20210430-20210430" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl8xL2ZyYWc6OGE0MTU3ZTViN2M5NDcxNmIyNjJhODFjOTE4Y2IzNDIvdGFibGU6NWVmYmU4OTVmZDFmNDc4NTk3ODBjYmZjMjVlMTJkYTYvdGFibGVyYW5nZTo1ZWZiZTg5NWZkMWY0Nzg1OTc4MGNiZmMyNWUxMmRhNl8zLTAtMS0xLTQy_9e816e3f-ce26-4f63-b114-181f8bd1c624">0.500% Senior Notes due 2021</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iacc41bc3fbb54680a429dc8cb29689bb_D20210430-20210430" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl8xL2ZyYWc6OGE0MTU3ZTViN2M5NDcxNmIyNjJhODFjOTE4Y2IzNDIvdGFibGU6NWVmYmU4OTVmZDFmNDc4NTk3ODBjYmZjMjVlMTJkYTYvdGFibGVyYW5nZTo1ZWZiZTg5NWZkMWY0Nzg1OTc4MGNiZmMyNWUxMmRhNl8zLTItMS0xLTQ1_ac4af252-c0d8-481b-8bdb-bf07a6a995f2">ABBV21C</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iacc41bc3fbb54680a429dc8cb29689bb_D20210430-20210430" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl8xL2ZyYWc6OGE0MTU3ZTViN2M5NDcxNmIyNjJhODFjOTE4Y2IzNDIvdGFibGU6NWVmYmU4OTVmZDFmNDc4NTk3ODBjYmZjMjVlMTJkYTYvdGFibGVyYW5nZTo1ZWZiZTg5NWZkMWY0Nzg1OTc4MGNiZmMyNWUxMmRhNl8zLTQtMS0xLTQ5_344a22db-129d-44d0-9c0d-57b650037664">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iacaeb3ad67e84bcab6f0ff402ffc8bdb_D20210430-20210430" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl8xL2ZyYWc6OGE0MTU3ZTViN2M5NDcxNmIyNjJhODFjOTE4Y2IzNDIvdGFibGU6NWVmYmU4OTVmZDFmNDc4NTk3ODBjYmZjMjVlMTJkYTYvdGFibGVyYW5nZTo1ZWZiZTg5NWZkMWY0Nzg1OTc4MGNiZmMyNWUxMmRhNl80LTAtMS0xLTQ0_bd140200-a030-47d1-90b4-f9e115ad38a7">1.500% Senior Notes due 2023</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iacaeb3ad67e84bcab6f0ff402ffc8bdb_D20210430-20210430" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl8xL2ZyYWc6OGE0MTU3ZTViN2M5NDcxNmIyNjJhODFjOTE4Y2IzNDIvdGFibGU6NWVmYmU4OTVmZDFmNDc4NTk3ODBjYmZjMjVlMTJkYTYvdGFibGVyYW5nZTo1ZWZiZTg5NWZkMWY0Nzg1OTc4MGNiZmMyNWUxMmRhNl80LTItMS0xLTQ4_6ad89589-d71b-421b-978e-cedf93db307f">ABBV23B</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iacaeb3ad67e84bcab6f0ff402ffc8bdb_D20210430-20210430" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl8xL2ZyYWc6OGE0MTU3ZTViN2M5NDcxNmIyNjJhODFjOTE4Y2IzNDIvdGFibGU6NWVmYmU4OTVmZDFmNDc4NTk3ODBjYmZjMjVlMTJkYTYvdGFibGVyYW5nZTo1ZWZiZTg5NWZkMWY0Nzg1OTc4MGNiZmMyNWUxMmRhNl80LTQtMS0xLTUy_aa48a20e-5ce3-43bc-bce2-cc05958f70c9">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i87f971760f124ed79664442df3b25e34_D20210430-20210430" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl8xL2ZyYWc6OGE0MTU3ZTViN2M5NDcxNmIyNjJhODFjOTE4Y2IzNDIvdGFibGU6NWVmYmU4OTVmZDFmNDc4NTk3ODBjYmZjMjVlMTJkYTYvdGFibGVyYW5nZTo1ZWZiZTg5NWZkMWY0Nzg1OTc4MGNiZmMyNWUxMmRhNl8zLTAtMS0xLTA_cbd80326-8a9d-482c-a6ab-5598139d8c20">1.375% Senior Notes due 2024</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i87f971760f124ed79664442df3b25e34_D20210430-20210430" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl8xL2ZyYWc6OGE0MTU3ZTViN2M5NDcxNmIyNjJhODFjOTE4Y2IzNDIvdGFibGU6NWVmYmU4OTVmZDFmNDc4NTk3ODBjYmZjMjVlMTJkYTYvdGFibGVyYW5nZTo1ZWZiZTg5NWZkMWY0Nzg1OTc4MGNiZmMyNWUxMmRhNl8zLTItMS0xLTA_9e2a841f-c4c2-42ce-aedc-71dcc3c1844c">ABBV24</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i87f971760f124ed79664442df3b25e34_D20210430-20210430" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl8xL2ZyYWc6OGE0MTU3ZTViN2M5NDcxNmIyNjJhODFjOTE4Y2IzNDIvdGFibGU6NWVmYmU4OTVmZDFmNDc4NTk3ODBjYmZjMjVlMTJkYTYvdGFibGVyYW5nZTo1ZWZiZTg5NWZkMWY0Nzg1OTc4MGNiZmMyNWUxMmRhNl8zLTQtMS0xLTA_a9ebb888-2e48-4806-bb5f-006ab0ef6b85">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib272ba06fa0d4b20b8126cadf25c8d44_D20210430-20210430" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl8xL2ZyYWc6OGE0MTU3ZTViN2M5NDcxNmIyNjJhODFjOTE4Y2IzNDIvdGFibGU6NWVmYmU4OTVmZDFmNDc4NTk3ODBjYmZjMjVlMTJkYTYvdGFibGVyYW5nZTo1ZWZiZTg5NWZkMWY0Nzg1OTc4MGNiZmMyNWUxMmRhNl82LTAtMS0xLTU0_e64fc861-0ea2-4d1b-ac19-c062a0b196cc">1.250% Senior Notes due 2024</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib272ba06fa0d4b20b8126cadf25c8d44_D20210430-20210430" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl8xL2ZyYWc6OGE0MTU3ZTViN2M5NDcxNmIyNjJhODFjOTE4Y2IzNDIvdGFibGU6NWVmYmU4OTVmZDFmNDc4NTk3ODBjYmZjMjVlMTJkYTYvdGFibGVyYW5nZTo1ZWZiZTg5NWZkMWY0Nzg1OTc4MGNiZmMyNWUxMmRhNl82LTItMS0xLTU4_28c15be2-c9ac-4306-8976-be9d1f22765d">ABBV24B</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib272ba06fa0d4b20b8126cadf25c8d44_D20210430-20210430" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl8xL2ZyYWc6OGE0MTU3ZTViN2M5NDcxNmIyNjJhODFjOTE4Y2IzNDIvdGFibGU6NWVmYmU4OTVmZDFmNDc4NTk3ODBjYmZjMjVlMTJkYTYvdGFibGVyYW5nZTo1ZWZiZTg5NWZkMWY0Nzg1OTc4MGNiZmMyNWUxMmRhNl82LTQtMS0xLTYw_9fadb21d-7047-4828-b465-848c9c24e5c2">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia74871cf5e6446fe98daf5c758cc9155_D20210430-20210430" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl8xL2ZyYWc6OGE0MTU3ZTViN2M5NDcxNmIyNjJhODFjOTE4Y2IzNDIvdGFibGU6NWVmYmU4OTVmZDFmNDc4NTk3ODBjYmZjMjVlMTJkYTYvdGFibGVyYW5nZTo1ZWZiZTg5NWZkMWY0Nzg1OTc4MGNiZmMyNWUxMmRhNl80LTAtMS0xLTA_54019f8d-507c-4bc8-ba2b-f5a12e68e646">0.750% Senior Notes due 2027</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia74871cf5e6446fe98daf5c758cc9155_D20210430-20210430" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl8xL2ZyYWc6OGE0MTU3ZTViN2M5NDcxNmIyNjJhODFjOTE4Y2IzNDIvdGFibGU6NWVmYmU4OTVmZDFmNDc4NTk3ODBjYmZjMjVlMTJkYTYvdGFibGVyYW5nZTo1ZWZiZTg5NWZkMWY0Nzg1OTc4MGNiZmMyNWUxMmRhNl80LTItMS0xLTA_3e7a3912-8b60-41cf-a01d-688e1ab23e56">ABBV27</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia74871cf5e6446fe98daf5c758cc9155_D20210430-20210430" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl8xL2ZyYWc6OGE0MTU3ZTViN2M5NDcxNmIyNjJhODFjOTE4Y2IzNDIvdGFibGU6NWVmYmU4OTVmZDFmNDc4NTk3ODBjYmZjMjVlMTJkYTYvdGFibGVyYW5nZTo1ZWZiZTg5NWZkMWY0Nzg1OTc4MGNiZmMyNWUxMmRhNl80LTQtMS0xLTA_26a4fecc-9039-4427-a9ce-6d21e493553c">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib7c02690c2a54e689107d2d34c8a565d_D20210430-20210430" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl8xL2ZyYWc6OGE0MTU3ZTViN2M5NDcxNmIyNjJhODFjOTE4Y2IzNDIvdGFibGU6NWVmYmU4OTVmZDFmNDc4NTk3ODBjYmZjMjVlMTJkYTYvdGFibGVyYW5nZTo1ZWZiZTg5NWZkMWY0Nzg1OTc4MGNiZmMyNWUxMmRhNl81LTAtMS0xLTA_dc1a7d1f-c2c0-4f75-8260-605e4123f2b2">2.125% Senior Notes due 2028</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib7c02690c2a54e689107d2d34c8a565d_D20210430-20210430" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl8xL2ZyYWc6OGE0MTU3ZTViN2M5NDcxNmIyNjJhODFjOTE4Y2IzNDIvdGFibGU6NWVmYmU4OTVmZDFmNDc4NTk3ODBjYmZjMjVlMTJkYTYvdGFibGVyYW5nZTo1ZWZiZTg5NWZkMWY0Nzg1OTc4MGNiZmMyNWUxMmRhNl81LTItMS0xLTA_96fa1d08-5e44-41b6-b1b3-50408f008264">ABBV28</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib7c02690c2a54e689107d2d34c8a565d_D20210430-20210430" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl8xL2ZyYWc6OGE0MTU3ZTViN2M5NDcxNmIyNjJhODFjOTE4Y2IzNDIvdGFibGU6NWVmYmU4OTVmZDFmNDc4NTk3ODBjYmZjMjVlMTJkYTYvdGFibGVyYW5nZTo1ZWZiZTg5NWZkMWY0Nzg1OTc4MGNiZmMyNWUxMmRhNl81LTQtMS0xLTA_a3f88292-0c72-4f03-af15-f5b7f9c4c87a">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i29032be1176d413e92e42e8adbbab24d_D20210430-20210430" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl8xL2ZyYWc6OGE0MTU3ZTViN2M5NDcxNmIyNjJhODFjOTE4Y2IzNDIvdGFibGU6NWVmYmU4OTVmZDFmNDc4NTk3ODBjYmZjMjVlMTJkYTYvdGFibGVyYW5nZTo1ZWZiZTg5NWZkMWY0Nzg1OTc4MGNiZmMyNWUxMmRhNl85LTAtMS0xLTYy_eecb898a-973f-49cb-932e-60df2c578612">2.625% Senior Notes due 2028</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i29032be1176d413e92e42e8adbbab24d_D20210430-20210430" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl8xL2ZyYWc6OGE0MTU3ZTViN2M5NDcxNmIyNjJhODFjOTE4Y2IzNDIvdGFibGU6NWVmYmU4OTVmZDFmNDc4NTk3ODBjYmZjMjVlMTJkYTYvdGFibGVyYW5nZTo1ZWZiZTg5NWZkMWY0Nzg1OTc4MGNiZmMyNWUxMmRhNl85LTItMS0xLTY1_16e686b6-3b28-47ae-a948-81d889266c2e">ABBV28B</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i29032be1176d413e92e42e8adbbab24d_D20210430-20210430" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl8xL2ZyYWc6OGE0MTU3ZTViN2M5NDcxNmIyNjJhODFjOTE4Y2IzNDIvdGFibGU6NWVmYmU4OTVmZDFmNDc4NTk3ODBjYmZjMjVlMTJkYTYvdGFibGVyYW5nZTo1ZWZiZTg5NWZkMWY0Nzg1OTc4MGNiZmMyNWUxMmRhNl85LTQtMS0xLTcw_1cda4753-645d-49c2-959c-45ff3e070e6e">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ifc45b489215749e7960282bf6274a10f_D20210430-20210430" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl8xL2ZyYWc6OGE0MTU3ZTViN2M5NDcxNmIyNjJhODFjOTE4Y2IzNDIvdGFibGU6NWVmYmU4OTVmZDFmNDc4NTk3ODBjYmZjMjVlMTJkYTYvdGFibGVyYW5nZTo1ZWZiZTg5NWZkMWY0Nzg1OTc4MGNiZmMyNWUxMmRhNl8xMC0wLTEtMS02NA_9bd670d8-c852-4611-9b5b-2167fd91dfe5">2.125% Senior Notes due 2029</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ifc45b489215749e7960282bf6274a10f_D20210430-20210430" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl8xL2ZyYWc6OGE0MTU3ZTViN2M5NDcxNmIyNjJhODFjOTE4Y2IzNDIvdGFibGU6NWVmYmU4OTVmZDFmNDc4NTk3ODBjYmZjMjVlMTJkYTYvdGFibGVyYW5nZTo1ZWZiZTg5NWZkMWY0Nzg1OTc4MGNiZmMyNWUxMmRhNl8xMC0yLTEtMS02OA_93cb9a5c-e223-4008-b7c3-cc4c9e996e87">ABBV29</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ifc45b489215749e7960282bf6274a10f_D20210430-20210430" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl8xL2ZyYWc6OGE0MTU3ZTViN2M5NDcxNmIyNjJhODFjOTE4Y2IzNDIvdGFibGU6NWVmYmU4OTVmZDFmNDc4NTk3ODBjYmZjMjVlMTJkYTYvdGFibGVyYW5nZTo1ZWZiZTg5NWZkMWY0Nzg1OTc4MGNiZmMyNWUxMmRhNl8xMC00LTEtMS03Mg_a5686c1c-c958-4c7e-ba04-c8d8c49568da">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8ed7fd5ee92346588519bb73fa7ddd03_D20210430-20210430" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl8xL2ZyYWc6OGE0MTU3ZTViN2M5NDcxNmIyNjJhODFjOTE4Y2IzNDIvdGFibGU6NWVmYmU4OTVmZDFmNDc4NTk3ODBjYmZjMjVlMTJkYTYvdGFibGVyYW5nZTo1ZWZiZTg5NWZkMWY0Nzg1OTc4MGNiZmMyNWUxMmRhNl82LTAtMS0xLTA_a420dca9-1756-4f87-b03f-78b8626f9cc3">1.250% Senior Notes due 2031</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8ed7fd5ee92346588519bb73fa7ddd03_D20210430-20210430" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl8xL2ZyYWc6OGE0MTU3ZTViN2M5NDcxNmIyNjJhODFjOTE4Y2IzNDIvdGFibGU6NWVmYmU4OTVmZDFmNDc4NTk3ODBjYmZjMjVlMTJkYTYvdGFibGVyYW5nZTo1ZWZiZTg5NWZkMWY0Nzg1OTc4MGNiZmMyNWUxMmRhNl82LTItMS0xLTA_3466121f-047f-4512-9b4e-b5749b3c4023">ABBV31</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8ed7fd5ee92346588519bb73fa7ddd03_D20210430-20210430" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl8xL2ZyYWc6OGE0MTU3ZTViN2M5NDcxNmIyNjJhODFjOTE4Y2IzNDIvdGFibGU6NWVmYmU4OTVmZDFmNDc4NTk3ODBjYmZjMjVlMTJkYTYvdGFibGVyYW5nZTo1ZWZiZTg5NWZkMWY0Nzg1OTc4MGNiZmMyNWUxMmRhNl82LTQtMS0xLTA_154251b1-6752-4f66-a24b-f9831e1e8f98">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule&#160;405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i372845ab48f94e268be1959a2195352e_D20210430-20210430" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl8xL2ZyYWc6OGE0MTU3ZTViN2M5NDcxNmIyNjJhODFjOTE4Y2IzNDIvdGV4dHJlZ2lvbjo4YTQxNTdlNWI3Yzk0NzE2YjI2MmE4MWM5MThjYjM0Ml8xODQ3_34950660-e2f6-431d-ad2e-bbcc431ee5cf">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:3pt;font-weight:400;line-height:120%">&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act.&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:3pt;font-weight:400;line-height:120%">&#160;&#160;&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i8aeb700ba8d3432bb188cb161c1da14f_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 2.02&#160;&#160;Results of Operations and Financial Condition</span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On April&#160;30, 2021, AbbVie Inc. issued a press release announcing financial results for the first quarter ended March 31, 2021.&#160; A copy of the press release is furnished as Exhibit&#160;99.1 to this report and incorporated herein by reference.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 9.01  Financial Statements and Exhibits</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d) Exhibits</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:11.363%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.745%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit No.</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none" href="abbv-20210331xexhibit991.htm">99.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none" href="abbv-20210331xexhibit991.htm">Press Release dat</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none" href="abbv-20210331xexhibit991.htm">ed </a><a style="-sec-extract:exhibit;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none" href="abbv-20210331xexhibit991.htm">April 30, 2021</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none" href="abbv-20210331xexhibit991.htm"> (furnished pursuant to Item 2.02).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).</span></td></tr></table></div><div style="padding-left:54pt;text-indent:-54pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">SIGNATURE</span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.437%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.170%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.237%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ABBVIE INC.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">April 30, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">/s/ Robert A. Michael</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Robert A. Michael</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Executive Vice President,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>abbv-20210331xexhibit991.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ifc8dabd797fa455389500cae1644740a_1"></div><div style="min-height:45pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><img alt="abbvieimage1a531a.jpg" src="abbvieimage1a531a.jpg" style="height:25px;margin-bottom:5pt;vertical-align:text-bottom;width:150px"></div><div><font style="color:#071d49;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font></div><div style="margin-top:24pt"><font style="color:#071d49;font-family:'Calibri',sans-serif;font-size:16pt;font-weight:700;line-height:120%">PRESS RELEASE</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:120%">AbbVie Reports First-Quarter 2021 Financial Results</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;   </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12.53pt">Reports First-Quarter Diluted EPS of $1.99 on a GAAP Basis&#59; Adjusted Diluted EPS of $2.95</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12.53pt">Delivers First-Quarter Net Revenues of $13.010 Billion on a GAAP Basis, an Increase of 51.0 Percent on a Reported Basis&#59; Adjusted Net Revenues Were $12.935 Billion</font></div><div style="padding-left:36pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12.53pt">First-Quarter Global Net Revenues from the Immunology Portfolio Were $5.744 Billion, an Increase of 12.9 Percent on a Reported Basis, or 11.8 Percent on an Operational Basis&#59; U.S. Humira Net Revenues Were $3.907 Billion, an Increase of 6.9 Percent&#59; Internationally, Humira Net Revenues Were $960 Million, a Decrease of 8.3 Percent on a Reported Basis, or 12.6 Percent on an Operational Basis, Due to Biosimilar Competition&#59; Global Skyrizi Net Revenues Were $574 Million&#59; Global Rinvoq Net Revenues Were $303 Million</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12.53pt">First-Quarter Global Net Revenues from the Hematologic Oncology Portfolio Were $1.673 Billion, an Increase of 8.0 Percent on a Reported Basis, or 7.3 Percent on an Operational Basis&#59; Global Imbruvica Net Revenues Were $1.268 Billion, an Increase of 2.9 Percent</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">with U.S. Net Revenues of $999 Million and International Profit Sharing of $269 Million&#59; Global Venclexta Net Revenues Were $405 Million</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12.53pt">First-Quarter Global Net Revenues from the Aesthetics Portfolio Were $1.141 Billion&#59; Global Botox Cosmetic Net Revenues Were $477 Million</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12.53pt">First-Quarter Global Net Revenues from the Neuroscience Portfolio Were $1.248 Billion&#59; Global Botox Therapeutic Net Revenues Were $532 Million&#59; Global Vraylar Net Revenues Were $346 Million</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12.53pt">Raises 2021 GAAP Diluted EPS Guidance Range from $6.69 to $6.89 to $7.27 to $7.47&#59; Raises 2021 Adjusted Diluted EPS Guidance Range from $12.32 to $12.52 to $12.37 to $12.57</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NORTH CHICAGO,&#160;Ill.,</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> April&#160;30, 2021 &#8211; AbbVie (NYSE&#58;ABBV) announced financial results for the first quarter ended March 31, 2021.</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#34;We are off to an excellent start to 2021, with strong performance across our core therapeutic areas and first quarter revenue and earnings results ahead of our expectations,&#8221; said Richard A. Gonzalez, chairman and chief executive officer, AbbVie. &#8220;Our new products are delivering impressive performance and we are on the cusp of potential commercial approvals for more than a dozen new products or indications over the next two years &#8211; including five expected approvals in 2021.&#34;</font></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Note&#58; &#34;Operational&#34; comparisons are presented at constant currency rates and reflect comparative local currency net revenues at the prior year's foreign exchange rates.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1</font></div></div></div><div id="ifc8dabd797fa455389500cae1644740a_4"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">First-Quarter Results</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">Worldwide GAAP net revenues were $13.010 billion, an increase of 51.0 percent on a reported basis. Worldwide adjusted net revenues of $12.935 billion increased 5.2 percent on a comparable operational basis.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">Global net revenues from the immunology portfolio were $5.744 billion, an increase of 12.9 percent on a reported basis, or 11.8 percent on an operational basis.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.25pt">Global Humira net revenues of $4.867 billion increased 3.5 percent on a reported basis, or 2.6 percent on an operational basis. U.S. Humira net revenues were $3.907 billion, an increase of 6.9 percent. Internationally, Humira net revenues were $960 million, a decrease of 8.3 percent on a reported basis, or 12.6 percent on an operational basis, due to biosimilar competition.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.25pt">Global Skyrizi net revenues were $574 million.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.25pt">Global Rinvoq net revenues were $303 million.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">Global net revenues from the hematologic oncology portfolio were $1.673 billion, an increase of 8.0 percent on a reported basis, or 7.3 percent on an operational basis. </font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.25pt">Global Imbruvica net revenues were $1.268 billion, an increase of 2.9 percent, with U.S. net revenues of $999 million and international profit sharing of $269 million. </font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.25pt">Global Venclexta net revenues were $405 million, an increase of 27.9 percent on a reported basis, or 24.5 percent on an operational basis. </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">Global net revenues from the aesthetics portfolio were $1.141 billion, an increase of 34.9 percent on a comparable operational basis.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.25pt">Global Botox Cosmetic net revenues were $477 million, an increase of 44.7 percent on a comparable operational basis.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">Global net revenues from the neuroscience portfolio were $1.248 billion, an increase of over 100.0 percent on a reported basis, or 10.9 percent on a comparable operational basis. </font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.25pt">Global Botox Therapeutic net revenues were $532 million, an increase of 7.0 percent on a comparable operational basis.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.25pt">Global Vraylar net revenues were $346 million, an increase of 21.2 percent on a comparable operational basis.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.25pt">Global Ubrelvy net revenues were $81 million.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">On a GAAP basis, the gross margin ratio in the first quarter was 67.6 percent. The adjusted gross margin ratio was 83.9 percent.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">On a GAAP basis, selling, general and administrative expense was 21.8 percent of net revenues. The adjusted SG&#38;A expense was 21.2 percent of net revenues. </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">On a GAAP basis, research and development expense was 13.7 percent of net revenues. The adjusted R&#38;D expense was 11.6 percent of net revenues, reflecting funding actions supporting all stages of our pipeline. </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">On a GAAP basis, the operating margin in the first quarter was 31.5 percent. The adjusted operating margin was 51.0 percent.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">On a GAAP basis, net interest expense was $622 million.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">On a GAAP basis, the tax rate in the quarter was 8.1 percent. The adjusted tax rate was 12.3 percent.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">Diluted EPS in the first quarter was $1.99 on a GAAP basis. Adjusted diluted EPS, excluding specified items, was $2.95.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.450%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.465%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.685%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Note&#58; &#34;Comparable Operational&#34; comparisons include full-quarter current year and prior year results for Allergan, which was acquired on May 8, 2020, as if the acquisition closed on January 1, 2019, and are presented at constant currency rates and reflect comparative local currency net revenues at the prior year&#8217;s foreign exchange rates. Refer to the Key Product Revenues schedules for further details. &#34;Operational&#34; comparisons are presented at constant currency rates and reflect comparative local currency net revenues at the prior year's foreign exchange rates. </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font></div></td></tr></table></div></div></div><div id="ifc8dabd797fa455389500cae1644740a_7"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Recent Events</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%;padding-left:14.15pt">AbbVie announced that it submitted applications to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) seeking approval for Skyrizi (risankizumab, 150 mg) for the treatment of adults with active psoriatic arthritis (PsA). The applications are supported by two Phase 3 studies in which Skyrizi demonstrated improved skin and joint symptoms and physical function, with a greater proportion of patients achieving minimal disease activity versus placebo. The safety profile of Skyrizi in these studies was generally consistent with the safety profile of Skyrizi in plaque psoriasis, with no new safety risks observed. Skyrizi is part of a collaboration between Boehringer Ingelheim and AbbVie, with AbbVie leading development and commercialization globally.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%;padding-left:12.53pt">AbbVie announced positive results from the Phase 3 induction study, U-ACCOMPLISH, which showed Rinvoq (upadacitinib, 45 mg, once daily) met the primary endpoint of clinical remission (per Adapted Mayo Score) at week 8 in adult patients with moderate to severe ulcerative colitis (UC). Additionally, all ranked secondary endpoints, including clinical, endoscopic and histologic outcomes, were met. U-ACCOMPLISH is the second of two Phase 3 induction studies to evaluate the safety and efficacy of Rinvoq in adults with moderate to severe UC and the results were consistent with findings from the first Phase 3 induction study, U-ACHIEVE. Safety results were also consistent with the previous Phase 3 induction study and the known profile of Rinvoq, with no new safety risks observed. Full results from the study will be presented at a future medical meeting and submitted for publication in a peer-reviewed journal. Results from the Phase 3 maintenance study and regulatory submissions are expected in 2H 2021.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%;padding-left:12.53pt">AbbVie announced that the FDA extended the review period for the supplemental New Drug Applications (sNDA) for Rinvoq in the treatment of adult patients with active PsA as well as in the treatment of adults and adolescents with moderate to severe atopic dermatitis (AD). AbbVie received information requests from the FDA for an updated assessment of the benefit-risk profile for Rinvoq in both indications. AbbVie responded to the requests and the FDA will require additional time for a full review of the submissions. The updated Prescription Drug User Fee Act (PDUFA) action dates have been extended three months to late 2Q 2021 for PsA and early 3Q 2021 for AD.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%;padding-left:12.53pt">AbbVie announced that the Committee for Medicinal Products for Human Use (CHMP) of the EMA adopted a positive opinion for Venclyxto (venetoclax) in combination with hypomethylating agents for the treatment of adult patients with newly-diagnosed acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy. The positive CHMP opinion is based on data from the VIALE-A and M14-358 trials and represents the third positive CHMP opinion for an extension of indications for Venclyxto. If approved by the European Commission (EC), Venclyxto in combination with hypomethylating agents would be a new regimen for patients with AML. The EC is expected to deliver its final decision on Venclyxto combination therapy for use in AML in 2Q 2021. Venetoclax is being developed by AbbVie and Roche and is jointly commercialized by AbbVie and Genentech, a member of the Roche Group, in the U.S. and by AbbVie outside of the U.S.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%;padding-left:12.53pt">AbbVie announced the FDA accepted its New Drug Application (NDA) for atogepant, an investigational orally administered calcitonin gene-related peptide (CGRP) receptor antagonist (gepant), for the preventive treatment of migraine in adults who meet criteria for episodic migraine. The NDA is supported by data from a clinical program evaluating the efficacy, safety and tolerability of orally administered atogepant in nearly 2,500 patients who experience 4-14 migraine days per month, including data from the pivotal Phase 3 ADVANCE study in which all active treatment arms of atogepant met their primary endpoint and the 30 and 60 mg doses met all six secondary endpoints with statistical significance. If approved, atogepant will be the first and only oral CGRP receptor antagonist specifically developed for the preventive treatment of migraine. AbbVie anticipates a regulatory decision in late 3Q 2021.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:107%">Recent Events (continued)</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%;padding-left:12.53pt">At the 2021 American Academy of Neurology (AAN) Annual Meeting, AbbVie presented data across its neuroscience portfolio. A total of 33 abstracts, including 4 oral presentations, were shared from a broad range of studies across the spectrum of migraine, advanced Parkinson&#8217;s disease (PD) and spasticity. Researchers presented migraine related data from the Phase 3 ADVANCE trial results on the safety and efficacy of atogepant in the preventive treatment of migraine, real-world data on the role of Botox (onabotulinumtoxinA) in combination with CGRP monoclonal antibodies (mAbs) for chronic migraine prevention, as well as data evaluating the efficacy and safety of Botox and Ubrelvy (ubrogepant). In addition, investigators presented the study design of the Phase 3 study assessing the efficacy and safety of the investigational treatment ABBV-951 (foslevodopa&#47;foscarbidopa), a levodopa&#47;carbidopa prodrug administered as a 24-hour continuous subcutaneous infusion, in people with advanced PD.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%;padding-left:12.53pt">AbbVie announced that it submitted a NDA to the FDA for investigational AGN-190584 (pilocarpine 1.25%) ophthalmic solution for the treatment of presbyopia. Presbyopia is a common, progressive condition that reduces the aging eye's ability to focus on near objects and affects nearly half of the adult U.S. population. The application is primarily based on data from two pivotal Phase 3 studies involving 750 patients. In both studies AGN-190584 met the primary endpoint reaching statistical significance in improvement in near vision without a loss of distance vision. If approved, AGN-190584 is expected to be the first eye drop to treat presbyopia and the FDA is expected to act on the NDA by the end of 2021.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%;padding-left:12.53pt">AbbVie announced the launch of Refresh Digital lubricant eye drops, a new lubricant eye drop formulated to specifically relieve dryness and irritation that may occur from prolonged screen time. Refresh Digital features proprietary HydroCell technology that supports all three layers of the tear film to keep eyes hydrated.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%;padding-left:12.53pt">Allergan Aesthetics announced the launch of SkinMedica Neck Correct Cream, the first product from the professional-grade skincare line formulated to address the specific biology of the skin on the neck and d&#233;collet&#233; area. SkinMedica Neck Correct Cream was designed to prevent the early signs as well as treat the visible appearance of moderate to severe neck aging. It is clinically proven to firm and tighten the look of crepey skin, prevent and reduce the look of sagging, smooth deep lines and wrinkles and enhance skin tone evenness.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%;padding-left:12.53pt">AbbVie and Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome editing biotechnology company, announced that they have entered into a collaboration and license agreement for the research and development of chimeric antigen receptor (CAR)-T cell therapeutics. Under the multi-year agreement, AbbVie will utilize Caribou's next-generation Cas12a CRISPR hybrid RNA-DNA genome editing and cell therapy technologies to research and develop two new CAR-T cell therapies directed to targets specified by AbbVie.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:107%">Full-Year 2021 Outlook</font></div><div style="margin-top:11pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">AbbVie is raising its GAAP diluted EPS guidance for the full-year 2021 from $6.69 to $6.89 to $7.27 to $7.47. AbbVie is raising its adjusted diluted EPS for the full-year 2021 from $12.32 to $12.52 to $12.37 to $12.57. The company's 2021 adjusted diluted EPS guidance excludes $5.10 per share of intangible asset amortization expense, non-cash charges for contingent consideration adjustments and other specified items.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About AbbVie</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas&#58; immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at </font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">www.abbvie.com</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Follow </font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#64;abbvie</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> on Twitter, </font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Facebook</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;or </font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">LinkedIn</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Conference Call</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">AbbVie will host an investor conference call today at 8&#58;00 a.m. Central time to discuss our first-quarter performance. The call will be webcast through AbbVie&#8217;s Investor Relations website at </font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">investors.abbvie.com</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. An archived edition of the call will be available after 11&#58;00 a.m. Central time.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Non-GAAP Financial Results</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Financial results for 2021 and 2020 are presented on both a reported and a non-GAAP basis. Reported results were prepared in accordance with GAAP and include all revenue and expenses recognized during the period. Non-GAAP results adjust for certain non-cash items and for factors that are unusual or unpredictable, and exclude those costs, expenses, and other specified items presented in the reconciliation tables later in this release. AbbVie&#8217;s management believes non-GAAP financial measures provide useful information to investors regarding AbbVie&#8217;s results of operations and assist management, analysts, and investors in evaluating the performance of the business. Non-GAAP financial measures should be considered in addition to, and not as a substitute for, measures of financial performance prepared in accordance with GAAP. The company&#8217;s 2021 financial guidance is also being provided on both a reported and a non-GAAP basis.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Forward-Looking Statements</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words &#34;believe,&#34; &#34;expect,&#34; &#34;anticipate,&#34; &#34;project&#34; and similar expressions, among others, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Such risks and uncertainties include, but are not limited to, the failure to realize the expected benefits of AbbVie&#8217;s acquisition of Allergan or to promptly and effectively integrate Allergan&#8217;s business, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, &#34;Risk Factors,&#34; of AbbVie's 2020 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.</font></div><div style="margin-top:11pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:60.724%"><tr><td style="width:1.0%"></td><td style="width:59.997%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.803%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Media&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Investors&#58;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Gentry Lassiter</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Liz Shea</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(224) 219-6670</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(847) 935-2211</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Todd Bosse</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(847) 936-1182</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Jeffrey Byrne</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(847) 938-2923</font></td></tr></table></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6</font></div></div></div><div id="ifc8dabd797fa455389500cae1644740a_10"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AbbVie Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Key Product Revenues</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Quarter Ended March 31, 2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(Unaudited)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:23.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% Change vs. 1Q20</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Revenues (in millions)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Reported</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Comparable Operational </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">a, b</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">U.S.</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Int&#8217;l.</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Total</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">U.S.</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Int'l.</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Total</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">U.S.</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Int'l</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Total</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ADJUSTED NET REVENUES</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">c</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$9,675</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$3,260</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$12,935</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">57.1%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">32.5%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">50.1%</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.3%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.7)%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.2%</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Immunology</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,633</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,111</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,744</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15.7</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.9</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15.7</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2.8)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11.8</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Humira</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,907</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">960</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,867</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.3)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.6)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Skyrizi</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">481</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">574</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.6</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#62;100.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.1</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.6</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#62;100.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88.9</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rinvoq</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#62;100.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#62;100.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#62;100.0</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#62;100.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#62;100.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#62;100.0</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Hematologic Oncology</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,224</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">449</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,673</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.8</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17.7</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.0</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.8</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14.9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.3</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Imbruvica</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">d</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">999</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,268</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Venclexta</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.9</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.6</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.5</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aesthetics</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">728</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">413</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,141</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">n&#47;m</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">n&#47;m</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">n&#47;m</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23.8</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">61.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">34.9</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Botox Cosmetic*</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">477</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n&#47;m</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n&#47;m</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n&#47;m</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.7</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.7</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Juvederm Collection*</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n&#47;m</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n&#47;m</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n&#47;m</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.6</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.0</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Aesthetics*</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n&#47;m</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n&#47;m</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n&#47;m</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.4</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.8</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Neuroscience</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,037</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">211</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,248</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#62;100.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#62;100.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#62;100.0</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.5</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.9</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Botox Therapeutic*</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">429</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">532</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n&#47;m</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n&#47;m</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n&#47;m</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vraylar*</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n&#47;m</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n&#47;a</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n&#47;m</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n&#47;a</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.2</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Duodopa</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.5)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.4)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ubrelvy*</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n&#47;m</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n&#47;a</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n&#47;m</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#62;100.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n&#47;a</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#62;100.0</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Neuroscience*</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n&#47;m</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n&#47;m</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n&#47;m</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.5)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.1)</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Eye Care</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">530</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">287</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">817</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">n&#47;m</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">n&#47;m</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">n&#47;m</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(12.7)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1.8)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9.2)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lumigan&#47;Ganfort*</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n&#47;m</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n&#47;m</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n&#47;m</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.4)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.7)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.1)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alphagan&#47;Combigan*</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n&#47;m</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n&#47;m</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n&#47;m</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.5)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.5)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restasis*</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n&#47;m</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n&#47;m</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n&#47;m</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.9)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.8)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Eye Care*</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n&#47;m</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n&#47;m</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n&#47;m</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.4)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Women's Health</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">177</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">180</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#62;100.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#62;100.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#62;100.0</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(19.6)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(61.0)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(21.2)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lo Loestrin*</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n&#47;m</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n&#47;m</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n&#47;m</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.2)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.1)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.1)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Orilissa&#47;Oriahnn</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.0)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.8</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.3)</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.0)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.8</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.5)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Women's Health*</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n&#47;m</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n&#47;m</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n&#47;m</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38.1)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100.0)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42.8)</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Key Products</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">294</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,315</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.4</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(19.1)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.4</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(7.3)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(25.1)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(11.7)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mavyret</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">415</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.9)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24.8)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.7)</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.9)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29.5)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28.4)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Creon</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n&#47;a</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n&#47;a</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lupron</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.1)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.3)</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.1)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.6)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Linzess&#47;Constella*</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n&#47;m</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n&#47;m</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n&#47;m</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.7</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.6)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.1</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Synthroid</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.8)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n&#47;a</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.8)</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.8)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n&#47;a</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.8)</font></td></tr></table></div><div style="margin-top:5pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">a   </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#34;Comparable Operational&#34; comparisons include full-quarter current year and prior year results for Allergan products, as if the acquisition closed on January 1, 2019, and are presented at constant currency rates that reflect comparative local currency net revenues at the prior year's foreign exchange rates. </font></div><div style="margin-top:5pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">b </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">  All historically reported Allergan revenues have been recast to conform to AbbVie's revenue recognition accounting policies and reporting conventions for certain rebates and discounts. Historically reported Allergan revenues also exclude Zenpep and Viokace product revenues, which were both divested as part of the acquisition, as well as specified items. </font></div><div style="margin-top:5pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">c    </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Adjusted net revenues exclude specified items. Refer to the Reconciliation of GAAP Reported to Non-GAAP Adjusted Information for further details. Percentage change is calculated using adjusted net revenues.</font></div><div style="margin-top:5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">d   </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Reflects profit sharing for Imbruvica international revenues.</font></div><div style="margin-top:5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">* Represents product(s) acquired as part of the Allergan acquisition.</font></div><div style="margin-top:5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">n&#47;a &#61; not applicable</font></div><div style="margin-top:5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">n&#47;m &#61; not meaningful</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7</font></div></div></div><div id="ifc8dabd797fa455389500cae1644740a_1099511627950"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AbbVie Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Consolidated Statements of Earnings</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Quarter Ended March 31, 2021 and 2020 </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(Unaudited) (In millions, except per share data)</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.361%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.015%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;First Quarter<br>Ended March 31</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,010&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,619&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,213&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,942&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,842&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,695&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,782&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,379&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating costs and expenses</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,907&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,016&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating earnings</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,103&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,603&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">622&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">428&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net foreign exchange loss</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income), net</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(395)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings before income tax expense</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,867&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,098&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">312&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net earnings</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,555&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,010&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net earnings attributable to noncontrolling interest</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net earnings attributable to AbbVie Inc.</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,553&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,010&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted earnings per share attributable to AbbVie Inc.</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.99&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.02&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted diluted earnings per share</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">a</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.95&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.42&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average diluted shares outstanding</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,775&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,484&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">a</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;Refer to the Reconciliation of GAAP Reported to Non-GAAP Adjusted Information for further details.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:10pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8</font></div></div></div><div id="ifc8dabd797fa455389500cae1644740a_1099511628005"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AbbVie Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Reconciliation of GAAP Reported to Non-GAAP Adjusted Information</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Quarter Ended March 31, 2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(Unaudited) (In millions, except per share data)</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:700;line-height:120%"> </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;&#160;Specified items impacted results as follows&#58;</font></div><div style="margin-bottom:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 4.37pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1Q21</font></td></tr><tr><td colspan="3" style="padding:2px 4.37pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</font></td></tr><tr><td colspan="3" style="padding:2px 4.37pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-tax</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After-tax</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">a</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EPS</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As reported (GAAP)</font></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,867</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,553</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.99</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted for specified items&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible asset amortization</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,009&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,682&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.94&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Milestones and other R&#38;D expenses</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.10&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition and integration costs</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.09&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&#38;D</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.03&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration </font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(343)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(343)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.19)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.01)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As adjusted (non-GAAP)</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,008</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,268</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.95</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">a &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Represents net earnings attributable to AbbVie Inc. </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milestones and other R&#38;D expenses include milestone payments for previously announced collaborations and the purchase of an FDA priority review voucher from a third party. Acquisition and integration costs reflect integration costs as well as amortization of the acquisition date fair value step-up for inventory related to the Allergan acquisition. Acquired IPR&#38;D primarily reflects upfront payments related to R&#38;D collaborations and licensing arrangements with third parties. Other primarily includes milestone revenue under an existing collaboration agreement, restructuring charges associated with streamlining global operations and COVID-19 related expenses.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.  </font><font style="color:#4c4c4c;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The impact of the specified items by line item was as follows&#58;&#160;</font></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.981%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1Q21</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SG&#38;A</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&#38;D</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&#38;D</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income), net</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As reported (GAAP)</font></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13,010</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,213</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,842</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,782</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">70</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(395)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted for specified items&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible asset amortization</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,009)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Milestones and other R&#38;D expenses</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(210)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition and integration costs</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&#38;D</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration </font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As adjusted</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(non-GAAP)</font></div></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,935</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,085</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,743</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,505</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(37)</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.     The adjusted tax rate for the first quarter of 2021 was 12.3 percent, as detailed below&#58;</font></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1Q21</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-tax<br>earnings</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income<br>taxes</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax rate</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As reported (GAAP)</font></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,867</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">312</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.1</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Specified items</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,141&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">426&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As adjusted</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(non-GAAP)</font></div></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,008</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">738</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.3</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AbbVie Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Reconciliation of GAAP Reported to Non-GAAP Adjusted Information</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Quarter Ended March 31, 2020</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(Unaudited) (In millions, except per share data)</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;&#160;Specified items impacted results as follows&#58;</font></div><div style="margin-bottom:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 4.37pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1Q20</font></td></tr><tr><td colspan="3" style="padding:2px 4.37pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</font></td></tr><tr><td colspan="3" style="padding:2px 4.37pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-tax</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After-tax</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">a</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EPS</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As reported (GAAP)</font></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,098</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,010</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.02</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted for specified items&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible asset amortization</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.24&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition related costs</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.11&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Milestones and other R&#38;D expenses</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.08&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration </font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.05&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(113)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.08)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As adjusted (non-GAAP)</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,003</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,613</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.42</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:3.9pt;font-weight:400;line-height:120%;position:relative;top:-2.1pt;vertical-align:baseline"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">a &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Represents net earnings attributable to AbbVie Inc. </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquisition related costs reflect transaction and financing costs related to the Allergan acquisition. Milestones and other R&#38;D expenses include milestone payments for previously announced collaborations and the purchase of an FDA priority review voucher from a third party. Other primarily includes the impacts of tax law changes, charitable contributions to support COVID-19 relief efforts and restructuring charges associated with streamlining global operations.</font></div><div style="margin-top:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.  </font><font style="color:#4c4c4c;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The impact of the specified items by line item was as follows&#58;&#160;</font></div><div style="margin-bottom:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.923%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:8.117%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1Q20</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SG&#38;A</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&#38;D</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income), net</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As reported (GAAP)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,942</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,695</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,379</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">428</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">72</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted for specified items&#58;</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible asset amortization</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(444)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition related costs</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(144)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Milestones and other R&#38;D expenses</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(135)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration </font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As adjusted</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(non-GAAP)</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,494</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,599</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,234</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">284</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.     The adjusted tax rate for the first quarter of 2020 was 9.7 percent, as detailed below&#58;</font></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1Q20</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-tax<br>earnings</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income<br>taxes</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax rate</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As reported (GAAP)</font></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,098</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">88</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.8</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Specified items</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">905&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As adjusted</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(non-GAAP)</font></div></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,003</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">390</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9.7</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>abbv-20210430.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:3e7f0185-a9a1-4b61-815f-c61e42d62e69,g:da78bc11-9ed2-4b3e-b8cf-99a0859a3322-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:abbv="http://www.abbvie.com/20210430" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.abbvie.com/20210430">
  <xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/exch/2020-01-31" schemaLocation="https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="abbv-20210430_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="abbv-20210430_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="abbv-20210430_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="abbv-20210430_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="DocumentandEntityInformationDocument" roleURI="http://www.abbvie.com/role/DocumentandEntityInformationDocument">
        <link:definition>0001001 - Document - Document and Entity Information Document</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="abbv_Sec1.250SeniorNotesdue2031Member" abstract="true" name="Sec1.250SeniorNotesdue2031Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="abbv_Sec1.375SeniorNotesDue2024Member" abstract="true" name="Sec1.375SeniorNotesDue2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="abbv_Sec2.125SeniorNotesdue2028Member" abstract="true" name="Sec2.125SeniorNotesdue2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="abbv_Sec0.750SeniorNotesDue2027Member" abstract="true" name="Sec0.750SeniorNotesDue2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="abbv_Sec2625SeniorNotesDue2028Member" abstract="true" name="Sec2625SeniorNotesDue2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="abbv_Sec2125SeniorNotesDue2029Member" abstract="true" name="Sec2125SeniorNotesDue2029Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="abbv_Sec0500SeniorNotesDue2021Member" abstract="true" name="Sec0500SeniorNotesDue2021Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="abbv_Sec1500SeniorNotesDue2023Member" abstract="true" name="Sec1500SeniorNotesDue2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="abbv_Sec1250SeniorNotesDue2024Member" abstract="true" name="Sec1250SeniorNotesDue2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>4
<FILENAME>abbv-20210430_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:3e7f0185-a9a1-4b61-815f-c61e42d62e69,g:da78bc11-9ed2-4b3e-b8cf-99a0859a3322-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.abbvie.com/role/DocumentandEntityInformationDocument" xlink:type="simple" xlink:href="abbv-20210430.xsd#DocumentandEntityInformationDocument"/>
  <link:calculationLink xlink:role="http://www.abbvie.com/role/DocumentandEntityInformationDocument" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>5
<FILENAME>abbv-20210430_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:3e7f0185-a9a1-4b61-815f-c61e42d62e69,g:da78bc11-9ed2-4b3e-b8cf-99a0859a3322-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.abbvie.com/role/DocumentandEntityInformationDocument" xlink:type="simple" xlink:href="abbv-20210430.xsd#DocumentandEntityInformationDocument"/>
  <link:definitionLink xlink:role="http://www.abbvie.com/role/DocumentandEntityInformationDocument" xlink:type="extended" id="i35ffffd1b043493d9942c76c53e4fa70_DocumentandEntityInformationDocument">
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_d1fef89b-2fa1-4329-bf13-77e34c2e5b37" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_56bde0dd-f1cf-457a-9c2b-3a786aacc448" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d1fef89b-2fa1-4329-bf13-77e34c2e5b37" xlink:to="loc_dei_DocumentType_56bde0dd-f1cf-457a-9c2b-3a786aacc448" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_f77d6078-6552-4a9a-a511-006789b1c7ba" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d1fef89b-2fa1-4329-bf13-77e34c2e5b37" xlink:to="loc_dei_DocumentPeriodEndDate_f77d6078-6552-4a9a-a511-006789b1c7ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_f679317c-2c41-4fea-a53a-0e0d9ce1e978" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d1fef89b-2fa1-4329-bf13-77e34c2e5b37" xlink:to="loc_dei_EntityRegistrantName_f679317c-2c41-4fea-a53a-0e0d9ce1e978" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_53f14885-b014-4926-8508-3b7188a468b8" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d1fef89b-2fa1-4329-bf13-77e34c2e5b37" xlink:to="loc_dei_EntityCentralIndexKey_53f14885-b014-4926-8508-3b7188a468b8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_dc8e3eff-abcd-4fdf-901b-74e9f2327328" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d1fef89b-2fa1-4329-bf13-77e34c2e5b37" xlink:to="loc_dei_AmendmentFlag_dc8e3eff-abcd-4fdf-901b-74e9f2327328" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_df852c1b-3369-47ca-99dc-4c4682e72adb" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d1fef89b-2fa1-4329-bf13-77e34c2e5b37" xlink:to="loc_dei_EntityIncorporationStateCountryCode_df852c1b-3369-47ca-99dc-4c4682e72adb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_458f355f-49c2-4577-b34e-4440c2aaeb11" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d1fef89b-2fa1-4329-bf13-77e34c2e5b37" xlink:to="loc_dei_EntityFileNumber_458f355f-49c2-4577-b34e-4440c2aaeb11" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_d4c45aff-2b63-44b1-9959-84b11bed42d1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d1fef89b-2fa1-4329-bf13-77e34c2e5b37" xlink:to="loc_dei_EntityTaxIdentificationNumber_d4c45aff-2b63-44b1-9959-84b11bed42d1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_99247abb-5527-4320-9ec4-4f61de576e10" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d1fef89b-2fa1-4329-bf13-77e34c2e5b37" xlink:to="loc_dei_EntityAddressAddressLine1_99247abb-5527-4320-9ec4-4f61de576e10" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_20469b03-a732-4a87-8d48-1d6efe699d47" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d1fef89b-2fa1-4329-bf13-77e34c2e5b37" xlink:to="loc_dei_EntityAddressCityOrTown_20469b03-a732-4a87-8d48-1d6efe699d47" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_506a0c24-1490-4b00-8e65-b6134b3a2ecb" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d1fef89b-2fa1-4329-bf13-77e34c2e5b37" xlink:to="loc_dei_EntityAddressStateOrProvince_506a0c24-1490-4b00-8e65-b6134b3a2ecb" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_1de8af5b-5fc5-4bd1-b9c9-93da32a6c49a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d1fef89b-2fa1-4329-bf13-77e34c2e5b37" xlink:to="loc_dei_EntityAddressPostalZipCode_1de8af5b-5fc5-4bd1-b9c9-93da32a6c49a" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_6a6cee0c-1818-4c65-a1d1-b7929d8cb335" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d1fef89b-2fa1-4329-bf13-77e34c2e5b37" xlink:to="loc_dei_CityAreaCode_6a6cee0c-1818-4c65-a1d1-b7929d8cb335" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_3c4d619a-e8cc-41e5-8b13-6e0fa823bd5e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d1fef89b-2fa1-4329-bf13-77e34c2e5b37" xlink:to="loc_dei_LocalPhoneNumber_3c4d619a-e8cc-41e5-8b13-6e0fa823bd5e" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_d830a8bd-c999-44f1-8cd8-058c416af0c6" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d1fef89b-2fa1-4329-bf13-77e34c2e5b37" xlink:to="loc_dei_WrittenCommunications_d830a8bd-c999-44f1-8cd8-058c416af0c6" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_8b9542e5-660d-4364-8cad-cdd6038e5b8a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d1fef89b-2fa1-4329-bf13-77e34c2e5b37" xlink:to="loc_dei_SolicitingMaterial_8b9542e5-660d-4364-8cad-cdd6038e5b8a" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_f45a27a9-b315-4fc0-99d5-f9ad3fb51dff" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d1fef89b-2fa1-4329-bf13-77e34c2e5b37" xlink:to="loc_dei_PreCommencementTenderOffer_f45a27a9-b315-4fc0-99d5-f9ad3fb51dff" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_9ebd4ebe-1cd1-46c6-b930-909f14bf5de8" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d1fef89b-2fa1-4329-bf13-77e34c2e5b37" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_9ebd4ebe-1cd1-46c6-b930-909f14bf5de8" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_eb3055f5-c4f7-4700-badd-94741cb2569f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d1fef89b-2fa1-4329-bf13-77e34c2e5b37" xlink:to="loc_dei_Security12bTitle_eb3055f5-c4f7-4700-badd-94741cb2569f" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_f9a02e75-2fbf-4087-9eb8-ebd6eb8e80f9" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d1fef89b-2fa1-4329-bf13-77e34c2e5b37" xlink:to="loc_dei_TradingSymbol_f9a02e75-2fbf-4087-9eb8-ebd6eb8e80f9" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_559afc2f-9e4e-47e2-9f48-ac5b2e3b21c3" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d1fef89b-2fa1-4329-bf13-77e34c2e5b37" xlink:to="loc_dei_SecurityExchangeName_559afc2f-9e4e-47e2-9f48-ac5b2e3b21c3" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_28c18cdc-c757-429a-b3ac-6a7a2abc68c6" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d1fef89b-2fa1-4329-bf13-77e34c2e5b37" xlink:to="loc_dei_EntityEmergingGrowthCompany_28c18cdc-c757-429a-b3ac-6a7a2abc68c6" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_d3b67d63-5025-4410-b8a7-c01943fe6215" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_EntityInformationLineItems_d1fef89b-2fa1-4329-bf13-77e34c2e5b37" xlink:to="loc_dei_EntitiesTable_d3b67d63-5025-4410-b8a7-c01943fe6215" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_d71ab306-1ce1-4e28-91ab-2c5253a6e12e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntitiesTable_d3b67d63-5025-4410-b8a7-c01943fe6215" xlink:to="loc_us-gaap_StatementClassOfStockAxis_d71ab306-1ce1-4e28-91ab-2c5253a6e12e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_d71ab306-1ce1-4e28-91ab-2c5253a6e12e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_d71ab306-1ce1-4e28-91ab-2c5253a6e12e" xlink:to="loc_us-gaap_ClassOfStockDomain_d71ab306-1ce1-4e28-91ab-2c5253a6e12e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_20bfdfcf-05bb-48d3-a599-4d23ee9c766e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_d71ab306-1ce1-4e28-91ab-2c5253a6e12e" xlink:to="loc_us-gaap_ClassOfStockDomain_20bfdfcf-05bb-48d3-a599-4d23ee9c766e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_0a980175-b916-4dc9-9121-efbf06a3d913" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_20bfdfcf-05bb-48d3-a599-4d23ee9c766e" xlink:to="loc_us-gaap_CommonStockMember_0a980175-b916-4dc9-9121-efbf06a3d913" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_Sec0500SeniorNotesDue2021Member_33b1303c-96b2-40a4-bcb5-bbab0d5b03fe" xlink:href="abbv-20210430.xsd#abbv_Sec0500SeniorNotesDue2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_20bfdfcf-05bb-48d3-a599-4d23ee9c766e" xlink:to="loc_abbv_Sec0500SeniorNotesDue2021Member_33b1303c-96b2-40a4-bcb5-bbab0d5b03fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_Sec1500SeniorNotesDue2023Member_cf42198c-4287-4a02-829d-f0ec496ccfbe" xlink:href="abbv-20210430.xsd#abbv_Sec1500SeniorNotesDue2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_20bfdfcf-05bb-48d3-a599-4d23ee9c766e" xlink:to="loc_abbv_Sec1500SeniorNotesDue2023Member_cf42198c-4287-4a02-829d-f0ec496ccfbe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_Sec1.375SeniorNotesDue2024Member_b31b3dc4-fd41-4070-928d-2587b567a107" xlink:href="abbv-20210430.xsd#abbv_Sec1.375SeniorNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_20bfdfcf-05bb-48d3-a599-4d23ee9c766e" xlink:to="loc_abbv_Sec1.375SeniorNotesDue2024Member_b31b3dc4-fd41-4070-928d-2587b567a107" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_Sec1250SeniorNotesDue2024Member_525988cc-46f6-403c-b1d3-57aedf6fbbf8" xlink:href="abbv-20210430.xsd#abbv_Sec1250SeniorNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_20bfdfcf-05bb-48d3-a599-4d23ee9c766e" xlink:to="loc_abbv_Sec1250SeniorNotesDue2024Member_525988cc-46f6-403c-b1d3-57aedf6fbbf8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_Sec0.750SeniorNotesDue2027Member_1b037521-df86-4010-98ef-abf31b0cce10" xlink:href="abbv-20210430.xsd#abbv_Sec0.750SeniorNotesDue2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_20bfdfcf-05bb-48d3-a599-4d23ee9c766e" xlink:to="loc_abbv_Sec0.750SeniorNotesDue2027Member_1b037521-df86-4010-98ef-abf31b0cce10" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_Sec2.125SeniorNotesdue2028Member_ad57e2e4-1b63-4173-83cb-1fc28c9c522a" xlink:href="abbv-20210430.xsd#abbv_Sec2.125SeniorNotesdue2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_20bfdfcf-05bb-48d3-a599-4d23ee9c766e" xlink:to="loc_abbv_Sec2.125SeniorNotesdue2028Member_ad57e2e4-1b63-4173-83cb-1fc28c9c522a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_Sec2625SeniorNotesDue2028Member_3b8049aa-03c0-42c5-9638-112986ff9c46" xlink:href="abbv-20210430.xsd#abbv_Sec2625SeniorNotesDue2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_20bfdfcf-05bb-48d3-a599-4d23ee9c766e" xlink:to="loc_abbv_Sec2625SeniorNotesDue2028Member_3b8049aa-03c0-42c5-9638-112986ff9c46" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_Sec2125SeniorNotesDue2029Member_4a82fe11-74de-42cb-8886-a2ce14b2a2df" xlink:href="abbv-20210430.xsd#abbv_Sec2125SeniorNotesDue2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_20bfdfcf-05bb-48d3-a599-4d23ee9c766e" xlink:to="loc_abbv_Sec2125SeniorNotesDue2029Member_4a82fe11-74de-42cb-8886-a2ce14b2a2df" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_Sec1.250SeniorNotesdue2031Member_5cc80a53-be3f-492b-ad45-111f13e21e35" xlink:href="abbv-20210430.xsd#abbv_Sec1.250SeniorNotesdue2031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_20bfdfcf-05bb-48d3-a599-4d23ee9c766e" xlink:to="loc_abbv_Sec1.250SeniorNotesdue2031Member_5cc80a53-be3f-492b-ad45-111f13e21e35" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityListingsExchangeAxis_3c64c300-7584-43e7-ab20-02ab2e648757" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityListingsExchangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntitiesTable_d3b67d63-5025-4410-b8a7-c01943fe6215" xlink:to="loc_dei_EntityListingsExchangeAxis_3c64c300-7584-43e7-ab20-02ab2e648757" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ExchangeDomain_3c64c300-7584-43e7-ab20-02ab2e648757_default" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_ExchangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_EntityListingsExchangeAxis_3c64c300-7584-43e7-ab20-02ab2e648757" xlink:to="loc_dei_ExchangeDomain_3c64c300-7584-43e7-ab20-02ab2e648757_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ExchangeDomain_fcd1bd14-711c-4d74-87ce-ab76fcaf08be" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_ExchangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_EntityListingsExchangeAxis_3c64c300-7584-43e7-ab20-02ab2e648757" xlink:to="loc_dei_ExchangeDomain_fcd1bd14-711c-4d74-87ce-ab76fcaf08be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exch_XNYS_c5138094-e565-4eb8-b911-7894cac46eb4" xlink:href="https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd#exch_XNYS"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_ExchangeDomain_fcd1bd14-711c-4d74-87ce-ab76fcaf08be" xlink:to="loc_exch_XNYS_c5138094-e565-4eb8-b911-7894cac46eb4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exch_XCHI_3ba29d4c-da7b-460d-8726-413bb4f70891" xlink:href="https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd#exch_XCHI"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_ExchangeDomain_fcd1bd14-711c-4d74-87ce-ab76fcaf08be" xlink:to="loc_exch_XCHI_3ba29d4c-da7b-460d-8726-413bb4f70891" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>abbv-20210430_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:3e7f0185-a9a1-4b61-815f-c61e42d62e69,g:da78bc11-9ed2-4b3e-b8cf-99a0859a3322-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_abbv_Sec2125SeniorNotesDue2029Member_bcfe0d6b-9cd3-402d-b1c4-76247adbfdd7_terseLabel_en-US" xlink:label="lab_abbv_Sec2125SeniorNotesDue2029Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sec 2.125 Senior Notes Due 2029</link:label>
    <link:label id="lab_abbv_Sec2125SeniorNotesDue2029Member_label_en-US" xlink:label="lab_abbv_Sec2125SeniorNotesDue2029Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sec 2.125 Senior Notes Due 2029 [Member]</link:label>
    <link:label id="lab_abbv_Sec2125SeniorNotesDue2029Member_documentation_en-US" xlink:label="lab_abbv_Sec2125SeniorNotesDue2029Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sec 2.125 Senior Notes Due 2029</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_Sec2125SeniorNotesDue2029Member" xlink:href="abbv-20210430.xsd#abbv_Sec2125SeniorNotesDue2029Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_Sec2125SeniorNotesDue2029Member" xlink:to="lab_abbv_Sec2125SeniorNotesDue2029Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_5ffda5d5-f309-4271-a146-b1f981eeabbb_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityListingsExchangeAxis_721dfe3e-6166-4da5-b243-4da90c7c5a17_terseLabel_en-US" xlink:label="lab_dei_EntityListingsExchangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Listings, Exchange [Axis]</link:label>
    <link:label id="lab_dei_EntityListingsExchangeAxis_label_en-US" xlink:label="lab_dei_EntityListingsExchangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Listings, Exchange [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityListingsExchangeAxis" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityListingsExchangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityListingsExchangeAxis" xlink:to="lab_dei_EntityListingsExchangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_Sec1.375SeniorNotesDue2024Member_0293d5eb-8521-44ea-9e75-c688585c8ce1_terseLabel_en-US" xlink:label="lab_abbv_Sec1.375SeniorNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sec 1.375 Senior Notes Due 2024</link:label>
    <link:label id="lab_abbv_Sec1.375SeniorNotesDue2024Member_label_en-US" xlink:label="lab_abbv_Sec1.375SeniorNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sec 1.375 Senior Notes Due 2024 [Member]</link:label>
    <link:label id="lab_abbv_Sec1.375SeniorNotesDue2024Member_documentation_en-US" xlink:label="lab_abbv_Sec1.375SeniorNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sec 1.375 Senior Notes Due 2024 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_Sec1.375SeniorNotesDue2024Member" xlink:href="abbv-20210430.xsd#abbv_Sec1.375SeniorNotesDue2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_Sec1.375SeniorNotesDue2024Member" xlink:to="lab_abbv_Sec1.375SeniorNotesDue2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_b3a0ad70-21be-4a0c-ae5a-5e9c594b8e48_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_65da137f-3cad-4595-bc4a-4dc33b7c10ad_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_a787aa46-bf9a-46c8-b9f1-b096ae6e6f0e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_ec24346f-f36d-491f-9a7a-00abbdfa0e58_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_90c55799-64d8-4e5e-a07b-15e5b1cce7a9_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_dbd0e665-28d4-415b-9a30-96132cd10f76_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_6d85158e-3fc5-469a-9cf6-699948f0e623_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_f3b37cdf-f42c-4caf-9afc-fab3b27b49df_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitiesTable_e7e82c78-d30c-4022-94ed-b5b938eac272_terseLabel_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entities [Table]</link:label>
    <link:label id="lab_dei_EntitiesTable_label_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitiesTable" xlink:to="lab_dei_EntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_Sec0500SeniorNotesDue2021Member_ad77f91d-e3d3-4809-b953-34b9d9feb680_terseLabel_en-US" xlink:label="lab_abbv_Sec0500SeniorNotesDue2021Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sec 0.500 Senior Notes Due 2021</link:label>
    <link:label id="lab_abbv_Sec0500SeniorNotesDue2021Member_label_en-US" xlink:label="lab_abbv_Sec0500SeniorNotesDue2021Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sec 0.500 Senior Notes Due 2021 [Member]</link:label>
    <link:label id="lab_abbv_Sec0500SeniorNotesDue2021Member_documentation_en-US" xlink:label="lab_abbv_Sec0500SeniorNotesDue2021Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sec 0.500 Senior Notes Due 2021</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_Sec0500SeniorNotesDue2021Member" xlink:href="abbv-20210430.xsd#abbv_Sec0500SeniorNotesDue2021Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_Sec0500SeniorNotesDue2021Member" xlink:to="lab_abbv_Sec0500SeniorNotesDue2021Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_2199a4c3-152b-4099-97e8-f959b1a14bdb_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_ExchangeDomain_758b1842-baba-449f-8e24-9f08e66a75d3_terseLabel_en-US" xlink:label="lab_dei_ExchangeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange [Domain]</link:label>
    <link:label id="lab_dei_ExchangeDomain_label_en-US" xlink:label="lab_dei_ExchangeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ExchangeDomain" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_ExchangeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_ExchangeDomain" xlink:to="lab_dei_ExchangeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_Sec1500SeniorNotesDue2023Member_c2c4e004-3f09-4f3c-a1da-83159d043b1a_terseLabel_en-US" xlink:label="lab_abbv_Sec1500SeniorNotesDue2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sec 1.500 Senior Notes Due 2023</link:label>
    <link:label id="lab_abbv_Sec1500SeniorNotesDue2023Member_label_en-US" xlink:label="lab_abbv_Sec1500SeniorNotesDue2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sec 1.500 Senior Notes Due 2023 [Member]</link:label>
    <link:label id="lab_abbv_Sec1500SeniorNotesDue2023Member_documentation_en-US" xlink:label="lab_abbv_Sec1500SeniorNotesDue2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sec 1.500 Senior Notes Due 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_Sec1500SeniorNotesDue2023Member" xlink:href="abbv-20210430.xsd#abbv_Sec1500SeniorNotesDue2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_Sec1500SeniorNotesDue2023Member" xlink:to="lab_abbv_Sec1500SeniorNotesDue2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_22b02471-e579-4a0d-b5f3-a396ff71c798_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_exch_XNYS_4ddb71ab-8988-4e8d-a2ca-80ba4fa062da_terseLabel_en-US" xlink:label="lab_exch_XNYS" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NEW YORK STOCK EXCHANGE, INC.</link:label>
    <link:label id="lab_exch_XNYS_label_en-US" xlink:label="lab_exch_XNYS" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NEW YORK STOCK EXCHANGE, INC. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exch_XNYS" xlink:href="https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd#exch_XNYS"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exch_XNYS" xlink:to="lab_exch_XNYS" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_Sec1250SeniorNotesDue2024Member_1191fcee-5f3a-4d73-8b28-c020eaed42bd_terseLabel_en-US" xlink:label="lab_abbv_Sec1250SeniorNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sec 1.250 Senior Notes Due 2024</link:label>
    <link:label id="lab_abbv_Sec1250SeniorNotesDue2024Member_label_en-US" xlink:label="lab_abbv_Sec1250SeniorNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sec 1.250 Senior Notes Due 2024 [Member]</link:label>
    <link:label id="lab_abbv_Sec1250SeniorNotesDue2024Member_documentation_en-US" xlink:label="lab_abbv_Sec1250SeniorNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sec 1.250 Senior Notes Due 2024</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_Sec1250SeniorNotesDue2024Member" xlink:href="abbv-20210430.xsd#abbv_Sec1250SeniorNotesDue2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_Sec1250SeniorNotesDue2024Member" xlink:to="lab_abbv_Sec1250SeniorNotesDue2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_895435fa-0810-4152-bee6-413855308ef0_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_0317baee-5a5e-4086-89db-ef5be0a3432f_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_Sec0.750SeniorNotesDue2027Member_76a4c74a-017a-480d-8854-9b360ffa202a_terseLabel_en-US" xlink:label="lab_abbv_Sec0.750SeniorNotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sec 0.750 Senior Notes Due 2027</link:label>
    <link:label id="lab_abbv_Sec0.750SeniorNotesDue2027Member_label_en-US" xlink:label="lab_abbv_Sec0.750SeniorNotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sec 0.750 Senior Notes Due 2027 [Member]</link:label>
    <link:label id="lab_abbv_Sec0.750SeniorNotesDue2027Member_documentation_en-US" xlink:label="lab_abbv_Sec0.750SeniorNotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sec 0.750 Senior Notes Due 2027 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_Sec0.750SeniorNotesDue2027Member" xlink:href="abbv-20210430.xsd#abbv_Sec0.750SeniorNotesDue2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_Sec0.750SeniorNotesDue2027Member" xlink:to="lab_abbv_Sec0.750SeniorNotesDue2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_018aa090-1abf-45dd-ab41-db9b4c7e5105_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_90085002-45af-441f-b8de-f0f0ac7e2d2f_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_5299db0e-d5ce-4e5a-b299-94d5e1a0ec0b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_5b1410be-b8be-447b-a69b-63511f73b624_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_08bfacd8-0bb8-488e-9ebb-e828541c9969_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_7c76ec59-c041-4f9d-bf0c-5be1b03bc1f6_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_b50eb4f6-bc1a-438a-8f30-a8321e71f77b_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_Sec1.250SeniorNotesdue2031Member_30275f44-0a39-4a4e-978e-97923b546b8c_terseLabel_en-US" xlink:label="lab_abbv_Sec1.250SeniorNotesdue2031Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sec 1.250 Senior Notes due 2031</link:label>
    <link:label id="lab_abbv_Sec1.250SeniorNotesdue2031Member_label_en-US" xlink:label="lab_abbv_Sec1.250SeniorNotesdue2031Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sec 1.250 Senior Notes due 2031 [Member]</link:label>
    <link:label id="lab_abbv_Sec1.250SeniorNotesdue2031Member_documentation_en-US" xlink:label="lab_abbv_Sec1.250SeniorNotesdue2031Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sec 1.250 Senior Notes due 2031 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_Sec1.250SeniorNotesdue2031Member" xlink:href="abbv-20210430.xsd#abbv_Sec1.250SeniorNotesdue2031Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_Sec1.250SeniorNotesdue2031Member" xlink:to="lab_abbv_Sec1.250SeniorNotesdue2031Member" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_Sec2.125SeniorNotesdue2028Member_37130e73-117b-489c-8cd2-ff0e6b905701_terseLabel_en-US" xlink:label="lab_abbv_Sec2.125SeniorNotesdue2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sec 2.125 Senior Notes due 2028</link:label>
    <link:label id="lab_abbv_Sec2.125SeniorNotesdue2028Member_label_en-US" xlink:label="lab_abbv_Sec2.125SeniorNotesdue2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sec 2.125 Senior Notes due 2028 [Member]</link:label>
    <link:label id="lab_abbv_Sec2.125SeniorNotesdue2028Member_documentation_en-US" xlink:label="lab_abbv_Sec2.125SeniorNotesdue2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sec 2.125 Senior Notes due 2028 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_Sec2.125SeniorNotesdue2028Member" xlink:href="abbv-20210430.xsd#abbv_Sec2.125SeniorNotesdue2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_Sec2.125SeniorNotesdue2028Member" xlink:to="lab_abbv_Sec2.125SeniorNotesdue2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_45bc1e7b-d101-42b2-91e7-4288cc59fb3b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_16e7dd69-a425-47fe-804b-5551471afb7a_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_000e67d1-777d-43b1-95a5-a8a54e3c0ced_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_90473eb7-d7ca-4d06-9106-7d6c201f8d7d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_Sec2625SeniorNotesDue2028Member_ed908e1f-d143-4f4a-8469-89b4e7975c35_terseLabel_en-US" xlink:label="lab_abbv_Sec2625SeniorNotesDue2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sec 2.625 Senior Notes Due 2028</link:label>
    <link:label id="lab_abbv_Sec2625SeniorNotesDue2028Member_label_en-US" xlink:label="lab_abbv_Sec2625SeniorNotesDue2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sec 2.625 Senior Notes Due 2028 [Member]</link:label>
    <link:label id="lab_abbv_Sec2625SeniorNotesDue2028Member_documentation_en-US" xlink:label="lab_abbv_Sec2625SeniorNotesDue2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sec 2.625 Senior Notes Due 2028</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_Sec2625SeniorNotesDue2028Member" xlink:href="abbv-20210430.xsd#abbv_Sec2625SeniorNotesDue2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_Sec2625SeniorNotesDue2028Member" xlink:to="lab_abbv_Sec2625SeniorNotesDue2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_95d03a90-dd99-40fd-82a4-367d5f6897b5_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_5d7b597c-cf84-4b0e-bb0e-696ed53105ec_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInformationLineItems_17b3f308-4488-45f5-9fe9-729f47490285_terseLabel_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:label id="lab_dei_EntityInformationLineItems_label_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInformationLineItems" xlink:to="lab_dei_EntityInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_exch_XCHI_c35caf25-f806-472b-927f-673369c36fc2_terseLabel_en-US" xlink:label="lab_exch_XCHI" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CHICAGO STOCK EXCHANGE, INC</link:label>
    <link:label id="lab_exch_XCHI_label_en-US" xlink:label="lab_exch_XCHI" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CHICAGO STOCK EXCHANGE, INC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exch_XCHI" xlink:href="https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd#exch_XCHI"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exch_XCHI" xlink:to="lab_exch_XCHI" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>abbv-20210430_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:3e7f0185-a9a1-4b61-815f-c61e42d62e69,g:da78bc11-9ed2-4b3e-b8cf-99a0859a3322-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.abbvie.com/role/DocumentandEntityInformationDocument" xlink:type="simple" xlink:href="abbv-20210430.xsd#DocumentandEntityInformationDocument"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/DocumentandEntityInformationDocument" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_64cb85e2-ab75-4ade-8660-bff99d3b33ff" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_d3b67d63-5025-4410-b8a7-c01943fe6215" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_64cb85e2-ab75-4ade-8660-bff99d3b33ff" xlink:to="loc_dei_EntitiesTable_d3b67d63-5025-4410-b8a7-c01943fe6215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_d71ab306-1ce1-4e28-91ab-2c5253a6e12e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_d3b67d63-5025-4410-b8a7-c01943fe6215" xlink:to="loc_us-gaap_StatementClassOfStockAxis_d71ab306-1ce1-4e28-91ab-2c5253a6e12e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_20bfdfcf-05bb-48d3-a599-4d23ee9c766e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_d71ab306-1ce1-4e28-91ab-2c5253a6e12e" xlink:to="loc_us-gaap_ClassOfStockDomain_20bfdfcf-05bb-48d3-a599-4d23ee9c766e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_0a980175-b916-4dc9-9121-efbf06a3d913" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_20bfdfcf-05bb-48d3-a599-4d23ee9c766e" xlink:to="loc_us-gaap_CommonStockMember_0a980175-b916-4dc9-9121-efbf06a3d913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_Sec0500SeniorNotesDue2021Member_33b1303c-96b2-40a4-bcb5-bbab0d5b03fe" xlink:href="abbv-20210430.xsd#abbv_Sec0500SeniorNotesDue2021Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_20bfdfcf-05bb-48d3-a599-4d23ee9c766e" xlink:to="loc_abbv_Sec0500SeniorNotesDue2021Member_33b1303c-96b2-40a4-bcb5-bbab0d5b03fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_Sec1500SeniorNotesDue2023Member_cf42198c-4287-4a02-829d-f0ec496ccfbe" xlink:href="abbv-20210430.xsd#abbv_Sec1500SeniorNotesDue2023Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_20bfdfcf-05bb-48d3-a599-4d23ee9c766e" xlink:to="loc_abbv_Sec1500SeniorNotesDue2023Member_cf42198c-4287-4a02-829d-f0ec496ccfbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_Sec1.375SeniorNotesDue2024Member_b31b3dc4-fd41-4070-928d-2587b567a107" xlink:href="abbv-20210430.xsd#abbv_Sec1.375SeniorNotesDue2024Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_20bfdfcf-05bb-48d3-a599-4d23ee9c766e" xlink:to="loc_abbv_Sec1.375SeniorNotesDue2024Member_b31b3dc4-fd41-4070-928d-2587b567a107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_Sec1250SeniorNotesDue2024Member_525988cc-46f6-403c-b1d3-57aedf6fbbf8" xlink:href="abbv-20210430.xsd#abbv_Sec1250SeniorNotesDue2024Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_20bfdfcf-05bb-48d3-a599-4d23ee9c766e" xlink:to="loc_abbv_Sec1250SeniorNotesDue2024Member_525988cc-46f6-403c-b1d3-57aedf6fbbf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_Sec0.750SeniorNotesDue2027Member_1b037521-df86-4010-98ef-abf31b0cce10" xlink:href="abbv-20210430.xsd#abbv_Sec0.750SeniorNotesDue2027Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_20bfdfcf-05bb-48d3-a599-4d23ee9c766e" xlink:to="loc_abbv_Sec0.750SeniorNotesDue2027Member_1b037521-df86-4010-98ef-abf31b0cce10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_Sec2.125SeniorNotesdue2028Member_ad57e2e4-1b63-4173-83cb-1fc28c9c522a" xlink:href="abbv-20210430.xsd#abbv_Sec2.125SeniorNotesdue2028Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_20bfdfcf-05bb-48d3-a599-4d23ee9c766e" xlink:to="loc_abbv_Sec2.125SeniorNotesdue2028Member_ad57e2e4-1b63-4173-83cb-1fc28c9c522a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_Sec2625SeniorNotesDue2028Member_3b8049aa-03c0-42c5-9638-112986ff9c46" xlink:href="abbv-20210430.xsd#abbv_Sec2625SeniorNotesDue2028Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_20bfdfcf-05bb-48d3-a599-4d23ee9c766e" xlink:to="loc_abbv_Sec2625SeniorNotesDue2028Member_3b8049aa-03c0-42c5-9638-112986ff9c46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_Sec2125SeniorNotesDue2029Member_4a82fe11-74de-42cb-8886-a2ce14b2a2df" xlink:href="abbv-20210430.xsd#abbv_Sec2125SeniorNotesDue2029Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_20bfdfcf-05bb-48d3-a599-4d23ee9c766e" xlink:to="loc_abbv_Sec2125SeniorNotesDue2029Member_4a82fe11-74de-42cb-8886-a2ce14b2a2df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_Sec1.250SeniorNotesdue2031Member_5cc80a53-be3f-492b-ad45-111f13e21e35" xlink:href="abbv-20210430.xsd#abbv_Sec1.250SeniorNotesdue2031Member"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_20bfdfcf-05bb-48d3-a599-4d23ee9c766e" xlink:to="loc_abbv_Sec1.250SeniorNotesdue2031Member_5cc80a53-be3f-492b-ad45-111f13e21e35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityListingsExchangeAxis_3c64c300-7584-43e7-ab20-02ab2e648757" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityListingsExchangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_d3b67d63-5025-4410-b8a7-c01943fe6215" xlink:to="loc_dei_EntityListingsExchangeAxis_3c64c300-7584-43e7-ab20-02ab2e648757" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ExchangeDomain_fcd1bd14-711c-4d74-87ce-ab76fcaf08be" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_ExchangeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityListingsExchangeAxis_3c64c300-7584-43e7-ab20-02ab2e648757" xlink:to="loc_dei_ExchangeDomain_fcd1bd14-711c-4d74-87ce-ab76fcaf08be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exch_XNYS_c5138094-e565-4eb8-b911-7894cac46eb4" xlink:href="https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd#exch_XNYS"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_ExchangeDomain_fcd1bd14-711c-4d74-87ce-ab76fcaf08be" xlink:to="loc_exch_XNYS_c5138094-e565-4eb8-b911-7894cac46eb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exch_XCHI_3ba29d4c-da7b-460d-8726-413bb4f70891" xlink:href="https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd#exch_XCHI"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_ExchangeDomain_fcd1bd14-711c-4d74-87ce-ab76fcaf08be" xlink:to="loc_exch_XCHI_3ba29d4c-da7b-460d-8726-413bb4f70891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_d1fef89b-2fa1-4329-bf13-77e34c2e5b37" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_d3b67d63-5025-4410-b8a7-c01943fe6215" xlink:to="loc_dei_EntityInformationLineItems_d1fef89b-2fa1-4329-bf13-77e34c2e5b37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_56bde0dd-f1cf-457a-9c2b-3a786aacc448" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d1fef89b-2fa1-4329-bf13-77e34c2e5b37" xlink:to="loc_dei_DocumentType_56bde0dd-f1cf-457a-9c2b-3a786aacc448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_f77d6078-6552-4a9a-a511-006789b1c7ba" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d1fef89b-2fa1-4329-bf13-77e34c2e5b37" xlink:to="loc_dei_DocumentPeriodEndDate_f77d6078-6552-4a9a-a511-006789b1c7ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_f679317c-2c41-4fea-a53a-0e0d9ce1e978" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d1fef89b-2fa1-4329-bf13-77e34c2e5b37" xlink:to="loc_dei_EntityRegistrantName_f679317c-2c41-4fea-a53a-0e0d9ce1e978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_53f14885-b014-4926-8508-3b7188a468b8" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d1fef89b-2fa1-4329-bf13-77e34c2e5b37" xlink:to="loc_dei_EntityCentralIndexKey_53f14885-b014-4926-8508-3b7188a468b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_dc8e3eff-abcd-4fdf-901b-74e9f2327328" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d1fef89b-2fa1-4329-bf13-77e34c2e5b37" xlink:to="loc_dei_AmendmentFlag_dc8e3eff-abcd-4fdf-901b-74e9f2327328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_df852c1b-3369-47ca-99dc-4c4682e72adb" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d1fef89b-2fa1-4329-bf13-77e34c2e5b37" xlink:to="loc_dei_EntityIncorporationStateCountryCode_df852c1b-3369-47ca-99dc-4c4682e72adb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_458f355f-49c2-4577-b34e-4440c2aaeb11" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d1fef89b-2fa1-4329-bf13-77e34c2e5b37" xlink:to="loc_dei_EntityFileNumber_458f355f-49c2-4577-b34e-4440c2aaeb11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_d4c45aff-2b63-44b1-9959-84b11bed42d1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d1fef89b-2fa1-4329-bf13-77e34c2e5b37" xlink:to="loc_dei_EntityTaxIdentificationNumber_d4c45aff-2b63-44b1-9959-84b11bed42d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_99247abb-5527-4320-9ec4-4f61de576e10" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d1fef89b-2fa1-4329-bf13-77e34c2e5b37" xlink:to="loc_dei_EntityAddressAddressLine1_99247abb-5527-4320-9ec4-4f61de576e10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_20469b03-a732-4a87-8d48-1d6efe699d47" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d1fef89b-2fa1-4329-bf13-77e34c2e5b37" xlink:to="loc_dei_EntityAddressCityOrTown_20469b03-a732-4a87-8d48-1d6efe699d47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_506a0c24-1490-4b00-8e65-b6134b3a2ecb" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d1fef89b-2fa1-4329-bf13-77e34c2e5b37" xlink:to="loc_dei_EntityAddressStateOrProvince_506a0c24-1490-4b00-8e65-b6134b3a2ecb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_1de8af5b-5fc5-4bd1-b9c9-93da32a6c49a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d1fef89b-2fa1-4329-bf13-77e34c2e5b37" xlink:to="loc_dei_EntityAddressPostalZipCode_1de8af5b-5fc5-4bd1-b9c9-93da32a6c49a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_6a6cee0c-1818-4c65-a1d1-b7929d8cb335" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d1fef89b-2fa1-4329-bf13-77e34c2e5b37" xlink:to="loc_dei_CityAreaCode_6a6cee0c-1818-4c65-a1d1-b7929d8cb335" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_3c4d619a-e8cc-41e5-8b13-6e0fa823bd5e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d1fef89b-2fa1-4329-bf13-77e34c2e5b37" xlink:to="loc_dei_LocalPhoneNumber_3c4d619a-e8cc-41e5-8b13-6e0fa823bd5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_d830a8bd-c999-44f1-8cd8-058c416af0c6" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d1fef89b-2fa1-4329-bf13-77e34c2e5b37" xlink:to="loc_dei_WrittenCommunications_d830a8bd-c999-44f1-8cd8-058c416af0c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_8b9542e5-660d-4364-8cad-cdd6038e5b8a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d1fef89b-2fa1-4329-bf13-77e34c2e5b37" xlink:to="loc_dei_SolicitingMaterial_8b9542e5-660d-4364-8cad-cdd6038e5b8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_f45a27a9-b315-4fc0-99d5-f9ad3fb51dff" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d1fef89b-2fa1-4329-bf13-77e34c2e5b37" xlink:to="loc_dei_PreCommencementTenderOffer_f45a27a9-b315-4fc0-99d5-f9ad3fb51dff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_9ebd4ebe-1cd1-46c6-b930-909f14bf5de8" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d1fef89b-2fa1-4329-bf13-77e34c2e5b37" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_9ebd4ebe-1cd1-46c6-b930-909f14bf5de8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_eb3055f5-c4f7-4700-badd-94741cb2569f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d1fef89b-2fa1-4329-bf13-77e34c2e5b37" xlink:to="loc_dei_Security12bTitle_eb3055f5-c4f7-4700-badd-94741cb2569f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_f9a02e75-2fbf-4087-9eb8-ebd6eb8e80f9" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d1fef89b-2fa1-4329-bf13-77e34c2e5b37" xlink:to="loc_dei_TradingSymbol_f9a02e75-2fbf-4087-9eb8-ebd6eb8e80f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_559afc2f-9e4e-47e2-9f48-ac5b2e3b21c3" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d1fef89b-2fa1-4329-bf13-77e34c2e5b37" xlink:to="loc_dei_SecurityExchangeName_559afc2f-9e4e-47e2-9f48-ac5b2e3b21c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_28c18cdc-c757-429a-b3ac-6a7a2abc68c6" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d1fef89b-2fa1-4329-bf13-77e34c2e5b37" xlink:to="loc_dei_EntityEmergingGrowthCompany_28c18cdc-c757-429a-b3ac-6a7a2abc68c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>abbvieimage1a531a.jpg
<TEXT>
begin 644 abbvieimage1a531a.jpg
M_]C_X  02D9)1@ ! 0$!&0$9  #__@ R35),3%]'4D%02$E#4SI;04)"5DE%
M74%"0E9)15]53D-/051?4$U37TQ/1T\N15!3_]L 0P ! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@ . %$ P$B  (1
M 0,1 ?_$ !\   (" P # 0$            *"0L"!P@!!08$ __$ $T0   &
M 0," P((!PH/ 0    $" P0%!@< " D1$@H3(10Q%1HB05%88=<6,G%R@9&8
M%Q@C)S-)E[&RLSE"4E598G:)E*&WR-'3\(?_Q  < 0 " P$! 0$
M   &!P,$!0((  '_Q  _$0 " @(! P($! ,#"0D    ! @,$!1$& !(A$S$'
M(D%1%",R815Q@4)RH187,U1C@I&4\$-%559B9972U/_:  P# 0 "$0,1 #\
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MMIA'(M): LE<P[B^4B91@N & J[9VV3,)%"*(KI"HW<)JH*JIFM L/6Y[?\
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MK.%RM>% 2\LV.MQ1J -DM(\*JH \[) UU)#F<18<1P93'32,0%CBNUI'8DZ
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M_?2]^M6E'A6SD_DVK;S-PS<[PHD]D1!W!Y:FE4FRH>9[2N+-=9$0)Y+=8!,
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M6,LNS3@Y%;0UM"Y6\12\@OQ5LC>QK,J];7,RVF&4W#O$'$!2.(?Y!OL^8?>
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M#V\[RC/T$MS5<<,A9L9 Q-HR".U(L,8'L9&+N%+;"+WN5;04KE83\(_O-N<
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MV5)&P3U#)X@Z&?P_+OO?;ODBD5DK#0IEH4A^\%F$U@;&R[ _=VE[3JDZE.0
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M._53?_M X)^]?1\7>YG?JIO_ -H'!/WKZM* ,F/N,0?R"4?ZM>?D?ZO_ "T
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M40B*BCHT-3_A-RHGW&CX%R<R:9S1K%Y#=@XG0FNX3$86K86(D,F/2/W^YKM
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MA],"A(\JRL =E>UCOJ,*F;T>938\5SCB)RSO<PFTJZ!&BF/\CUB^RD-66H)
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M7&QDN0MM<Q/N(JTA6UEF,;G_ &FO;O;*U)Q)CD.FY;V[%)"V>,AGWR3&A[W
M5Y8JP&1>PY52_*-&I>$<OS%22+!.U>[C)>Y5K7H3.(%8@LD+"1"(VV?RG,D0
M))5%)),?*^-8RRK98+-5OHT8-BI*(6DV0H:4=C!G ]G 5C_:+#QU]9#<X'-K
MC,48IQN>S415NP"/3:9&PI09^1!!JX$AEUE;CB125=OR+I';N)-VNX>',55!
MPN=0#@'T'Q@[FP^LU8/V;\*?=%HT:>$6#X_,BR/Q[!%G\L?X54\G:CZQD_\
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92?U7,$?=)(B-(YTFV=M#N8[.SKR3OK__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>abbv-20210430_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:abbv="http://www.abbvie.com/20210430"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="abbv-20210430.xsd" xlink:type="simple"/>
    <context id="i372845ab48f94e268be1959a2195352e_D20210430-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
        </entity>
        <period>
            <startDate>2021-04-30</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="i2e3151e7fbc24bb8ab5b9d54d0894a99_D20210430-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XCHI</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-30</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="i10cf4baaf38643babf7c0c0f6190fb60_D20210430-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNYS</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-30</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="iacc41bc3fbb54680a429dc8cb29689bb_D20210430-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abbv:Sec0500SeniorNotesDue2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNYS</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-30</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="iacaeb3ad67e84bcab6f0ff402ffc8bdb_D20210430-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abbv:Sec1500SeniorNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNYS</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-30</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="i87f971760f124ed79664442df3b25e34_D20210430-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abbv:Sec1.375SeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNYS</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-30</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="ib272ba06fa0d4b20b8126cadf25c8d44_D20210430-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abbv:Sec1250SeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNYS</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-30</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="ia74871cf5e6446fe98daf5c758cc9155_D20210430-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abbv:Sec0.750SeniorNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNYS</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-30</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="ib7c02690c2a54e689107d2d34c8a565d_D20210430-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abbv:Sec2.125SeniorNotesdue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNYS</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-30</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="i29032be1176d413e92e42e8adbbab24d_D20210430-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abbv:Sec2625SeniorNotesDue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNYS</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-30</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="ifc45b489215749e7960282bf6274a10f_D20210430-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abbv:Sec2125SeniorNotesDue2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNYS</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-30</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="i8ed7fd5ee92346588519bb73fa7ddd03_D20210430-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abbv:Sec1.250SeniorNotesdue2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNYS</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-30</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="i372845ab48f94e268be1959a2195352e_D20210430-20210430"
      id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl80L2ZyYWc6NTQ2NDhmYmIwYzNlNDIzM2E1OWQ3OWYwYWVhMjBjNDAvdGFibGU6MWFmMWUxYWEwYzg4NDYyMDg2YzEzNjJiNTljMDQyNjcvdGFibGVyYW5nZToxYWYxZTFhYTBjODg0NjIwODZjMTM2MmI1OWMwNDI2N18xLTEtMS0xLTA_d99a2d43-9af8-4b1a-bf41-0f16c4482780">0001551152</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="i372845ab48f94e268be1959a2195352e_D20210430-20210430"
      id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl80L2ZyYWc6NTQ2NDhmYmIwYzNlNDIzM2E1OWQ3OWYwYWVhMjBjNDAvdGFibGU6MWFmMWUxYWEwYzg4NDYyMDg2YzEzNjJiNTljMDQyNjcvdGFibGVyYW5nZToxYWYxZTFhYTBjODg0NjIwODZjMTM2MmI1OWMwNDI2N18yLTEtMS0xLTA_a36a37f6-d5b7-4b07-999b-d7829b67244d">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="i372845ab48f94e268be1959a2195352e_D20210430-20210430"
      id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl8xL2ZyYWc6OGE0MTU3ZTViN2M5NDcxNmIyNjJhODFjOTE4Y2IzNDIvdGV4dHJlZ2lvbjo4YTQxNTdlNWI3Yzk0NzE2YjI2MmE4MWM5MThjYjM0Ml8xODQ4_070e1a23-d35e-4554-84e9-3c18b19fc07e">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="i372845ab48f94e268be1959a2195352e_D20210430-20210430"
      id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl8xL2ZyYWc6OGE0MTU3ZTViN2M5NDcxNmIyNjJhODFjOTE4Y2IzNDIvdGV4dHJlZ2lvbjo4YTQxNTdlNWI3Yzk0NzE2YjI2MmE4MWM5MThjYjM0Ml8yODU_ecaec868-534b-4b0c-b19f-4d1ea4805929">2021-04-30</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="i372845ab48f94e268be1959a2195352e_D20210430-20210430"
      id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl8xL2ZyYWc6OGE0MTU3ZTViN2M5NDcxNmIyNjJhODFjOTE4Y2IzNDIvdGV4dHJlZ2lvbjo4YTQxNTdlNWI3Yzk0NzE2YjI2MmE4MWM5MThjYjM0Ml8xODUx_6c10018c-c119-459a-a550-3010630f7615">ABBVIE INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i372845ab48f94e268be1959a2195352e_D20210430-20210430"
      id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl8xL2ZyYWc6OGE0MTU3ZTViN2M5NDcxNmIyNjJhODFjOTE4Y2IzNDIvdGFibGU6N2YyMzY0ZDQ2ODkyNDhhMGJlYjQ4M2VmNWNkYjI3NWQvdGFibGVyYW5nZTo3ZjIzNjRkNDY4OTI0OGEwYmViNDgzZWY1Y2RiMjc1ZF8wLTAtMS0xLTA_2c70bc84-6a91-4d03-8654-e74c4dbc9a64">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="i372845ab48f94e268be1959a2195352e_D20210430-20210430"
      id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl8xL2ZyYWc6OGE0MTU3ZTViN2M5NDcxNmIyNjJhODFjOTE4Y2IzNDIvdGFibGU6N2YyMzY0ZDQ2ODkyNDhhMGJlYjQ4M2VmNWNkYjI3NWQvdGFibGVyYW5nZTo3ZjIzNjRkNDY4OTI0OGEwYmViNDgzZWY1Y2RiMjc1ZF8wLTItMS0xLTA_3eae6238-bdf8-4a32-8451-eb7e7f9061a6">001-35565</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="i372845ab48f94e268be1959a2195352e_D20210430-20210430"
      id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl8xL2ZyYWc6OGE0MTU3ZTViN2M5NDcxNmIyNjJhODFjOTE4Y2IzNDIvdGFibGU6N2YyMzY0ZDQ2ODkyNDhhMGJlYjQ4M2VmNWNkYjI3NWQvdGFibGVyYW5nZTo3ZjIzNjRkNDY4OTI0OGEwYmViNDgzZWY1Y2RiMjc1ZF8wLTQtMS0xLTA_91610947-5155-4811-ad10-1a6b08d31cc2">32-0375147</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i372845ab48f94e268be1959a2195352e_D20210430-20210430"
      id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl8xL2ZyYWc6OGE0MTU3ZTViN2M5NDcxNmIyNjJhODFjOTE4Y2IzNDIvdGV4dHJlZ2lvbjo4YTQxNTdlNWI3Yzk0NzE2YjI2MmE4MWM5MThjYjM0Ml8xODUw_787ef247-42bc-46e9-a154-bf58c79f159c">1 North Waukegan Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i372845ab48f94e268be1959a2195352e_D20210430-20210430"
      id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl8xL2ZyYWc6OGE0MTU3ZTViN2M5NDcxNmIyNjJhODFjOTE4Y2IzNDIvdGV4dHJlZ2lvbjo4YTQxNTdlNWI3Yzk0NzE2YjI2MmE4MWM5MThjYjM0Ml8xODU1_e2a989f1-74b1-4e9c-bda0-26010d3a4ba6">North Chicago</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i372845ab48f94e268be1959a2195352e_D20210430-20210430"
      id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl8xL2ZyYWc6OGE0MTU3ZTViN2M5NDcxNmIyNjJhODFjOTE4Y2IzNDIvdGV4dHJlZ2lvbjo4YTQxNTdlNWI3Yzk0NzE2YjI2MmE4MWM5MThjYjM0Ml8xODQ0_3fafd611-c958-48ea-8858-6fb0e6974245">IL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i372845ab48f94e268be1959a2195352e_D20210430-20210430"
      id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl8xL2ZyYWc6OGE0MTU3ZTViN2M5NDcxNmIyNjJhODFjOTE4Y2IzNDIvdGV4dHJlZ2lvbjo4YTQxNTdlNWI3Yzk0NzE2YjI2MmE4MWM5MThjYjM0Ml8xODQ1_c359225a-337b-47c9-a7fb-1c651b3effd7">60064-6400</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i372845ab48f94e268be1959a2195352e_D20210430-20210430"
      id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl8xL2ZyYWc6OGE0MTU3ZTViN2M5NDcxNmIyNjJhODFjOTE4Y2IzNDIvdGV4dHJlZ2lvbjo4YTQxNTdlNWI3Yzk0NzE2YjI2MmE4MWM5MThjYjM0Ml8xODQ2_e63071bf-da37-423d-8c3c-61440df47ab7">847</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i372845ab48f94e268be1959a2195352e_D20210430-20210430"
      id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl8xL2ZyYWc6OGE0MTU3ZTViN2M5NDcxNmIyNjJhODFjOTE4Y2IzNDIvdGV4dHJlZ2lvbjo4YTQxNTdlNWI3Yzk0NzE2YjI2MmE4MWM5MThjYjM0Ml8xODU2_f850c349-a63d-4985-a919-c42e7cf3f5f9">932-7900</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="i372845ab48f94e268be1959a2195352e_D20210430-20210430"
      id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl8xL2ZyYWc6OGE0MTU3ZTViN2M5NDcxNmIyNjJhODFjOTE4Y2IzNDIvdGV4dHJlZ2lvbjo4YTQxNTdlNWI3Yzk0NzE2YjI2MmE4MWM5MThjYjM0Ml8xODQ5_ec233757-5deb-4319-af1e-c6be4480ef58">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="i372845ab48f94e268be1959a2195352e_D20210430-20210430"
      id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl8xL2ZyYWc6OGE0MTU3ZTViN2M5NDcxNmIyNjJhODFjOTE4Y2IzNDIvdGV4dHJlZ2lvbjo4YTQxNTdlNWI3Yzk0NzE2YjI2MmE4MWM5MThjYjM0Ml8xODUy_74dc11d1-e946-4ca3-9541-94f92116f772">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="i372845ab48f94e268be1959a2195352e_D20210430-20210430"
      id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl8xL2ZyYWc6OGE0MTU3ZTViN2M5NDcxNmIyNjJhODFjOTE4Y2IzNDIvdGV4dHJlZ2lvbjo4YTQxNTdlNWI3Yzk0NzE2YjI2MmE4MWM5MThjYjM0Ml8xODUz_cb215879-0c43-4202-bf8d-7e044e3ed0f5">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="i372845ab48f94e268be1959a2195352e_D20210430-20210430"
      id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl8xL2ZyYWc6OGE0MTU3ZTViN2M5NDcxNmIyNjJhODFjOTE4Y2IzNDIvdGV4dHJlZ2lvbjo4YTQxNTdlNWI3Yzk0NzE2YjI2MmE4MWM5MThjYjM0Ml8xODU0_3642f344-d344-437f-84ba-7bb5ca3ce316">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="i2e3151e7fbc24bb8ab5b9d54d0894a99_D20210430-20210430"
      id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl8xL2ZyYWc6OGE0MTU3ZTViN2M5NDcxNmIyNjJhODFjOTE4Y2IzNDIvdGFibGU6NWVmYmU4OTVmZDFmNDc4NTk3ODBjYmZjMjVlMTJkYTYvdGFibGVyYW5nZTo1ZWZiZTg5NWZkMWY0Nzg1OTc4MGNiZmMyNWUxMmRhNl8xLTAtMS0xLTA_4e7af9ce-dd3d-4f67-b75d-e9db26b893f9">Common Stock, $0.01 Par Value</dei:Security12bTitle>
    <dei:Security12bTitle
      contextRef="i10cf4baaf38643babf7c0c0f6190fb60_D20210430-20210430"
      id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl8xL2ZyYWc6OGE0MTU3ZTViN2M5NDcxNmIyNjJhODFjOTE4Y2IzNDIvdGFibGU6NWVmYmU4OTVmZDFmNDc4NTk3ODBjYmZjMjVlMTJkYTYvdGFibGVyYW5nZTo1ZWZiZTg5NWZkMWY0Nzg1OTc4MGNiZmMyNWUxMmRhNl8xLTAtMS0xLTA_eb4d8039-376a-43f6-8c53-6df8f8f0a8a1">Common Stock, $0.01 Par Value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i2e3151e7fbc24bb8ab5b9d54d0894a99_D20210430-20210430"
      id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl8xL2ZyYWc6OGE0MTU3ZTViN2M5NDcxNmIyNjJhODFjOTE4Y2IzNDIvdGFibGU6NWVmYmU4OTVmZDFmNDc4NTk3ODBjYmZjMjVlMTJkYTYvdGFibGVyYW5nZTo1ZWZiZTg5NWZkMWY0Nzg1OTc4MGNiZmMyNWUxMmRhNl8xLTItMS0xLTA_5bcac279-3c62-4917-8bef-2659d4aa937c">ABBV</dei:TradingSymbol>
    <dei:TradingSymbol
      contextRef="i10cf4baaf38643babf7c0c0f6190fb60_D20210430-20210430"
      id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl8xL2ZyYWc6OGE0MTU3ZTViN2M5NDcxNmIyNjJhODFjOTE4Y2IzNDIvdGFibGU6NWVmYmU4OTVmZDFmNDc4NTk3ODBjYmZjMjVlMTJkYTYvdGFibGVyYW5nZTo1ZWZiZTg5NWZkMWY0Nzg1OTc4MGNiZmMyNWUxMmRhNl8xLTItMS0xLTA_6b350c0d-b591-4527-9aa1-fdbf615c5dd0">ABBV</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i10cf4baaf38643babf7c0c0f6190fb60_D20210430-20210430"
      id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl8xL2ZyYWc6OGE0MTU3ZTViN2M5NDcxNmIyNjJhODFjOTE4Y2IzNDIvdGFibGU6NWVmYmU4OTVmZDFmNDc4NTk3ODBjYmZjMjVlMTJkYTYvdGFibGVyYW5nZTo1ZWZiZTg5NWZkMWY0Nzg1OTc4MGNiZmMyNWUxMmRhNl8xLTQtMS0xLTA_1dc2d84a-4c44-43bb-bea2-5c2a75e7efd2">NYSE</dei:SecurityExchangeName>
    <dei:SecurityExchangeName
      contextRef="i2e3151e7fbc24bb8ab5b9d54d0894a99_D20210430-20210430"
      id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl8xL2ZyYWc6OGE0MTU3ZTViN2M5NDcxNmIyNjJhODFjOTE4Y2IzNDIvdGFibGU6NWVmYmU4OTVmZDFmNDc4NTk3ODBjYmZjMjVlMTJkYTYvdGFibGVyYW5nZTo1ZWZiZTg5NWZkMWY0Nzg1OTc4MGNiZmMyNWUxMmRhNl8yLTQtMS0xLTA_217ab4c0-f15e-498e-8bb0-6cfaa7990a43">CHX</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="iacc41bc3fbb54680a429dc8cb29689bb_D20210430-20210430"
      id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl8xL2ZyYWc6OGE0MTU3ZTViN2M5NDcxNmIyNjJhODFjOTE4Y2IzNDIvdGFibGU6NWVmYmU4OTVmZDFmNDc4NTk3ODBjYmZjMjVlMTJkYTYvdGFibGVyYW5nZTo1ZWZiZTg5NWZkMWY0Nzg1OTc4MGNiZmMyNWUxMmRhNl8zLTAtMS0xLTQy_9e816e3f-ce26-4f63-b114-181f8bd1c624">0.500% Senior Notes due 2021</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="iacc41bc3fbb54680a429dc8cb29689bb_D20210430-20210430"
      id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl8xL2ZyYWc6OGE0MTU3ZTViN2M5NDcxNmIyNjJhODFjOTE4Y2IzNDIvdGFibGU6NWVmYmU4OTVmZDFmNDc4NTk3ODBjYmZjMjVlMTJkYTYvdGFibGVyYW5nZTo1ZWZiZTg5NWZkMWY0Nzg1OTc4MGNiZmMyNWUxMmRhNl8zLTItMS0xLTQ1_ac4af252-c0d8-481b-8bdb-bf07a6a995f2">ABBV21C</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="iacc41bc3fbb54680a429dc8cb29689bb_D20210430-20210430"
      id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl8xL2ZyYWc6OGE0MTU3ZTViN2M5NDcxNmIyNjJhODFjOTE4Y2IzNDIvdGFibGU6NWVmYmU4OTVmZDFmNDc4NTk3ODBjYmZjMjVlMTJkYTYvdGFibGVyYW5nZTo1ZWZiZTg5NWZkMWY0Nzg1OTc4MGNiZmMyNWUxMmRhNl8zLTQtMS0xLTQ5_344a22db-129d-44d0-9c0d-57b650037664">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="iacaeb3ad67e84bcab6f0ff402ffc8bdb_D20210430-20210430"
      id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl8xL2ZyYWc6OGE0MTU3ZTViN2M5NDcxNmIyNjJhODFjOTE4Y2IzNDIvdGFibGU6NWVmYmU4OTVmZDFmNDc4NTk3ODBjYmZjMjVlMTJkYTYvdGFibGVyYW5nZTo1ZWZiZTg5NWZkMWY0Nzg1OTc4MGNiZmMyNWUxMmRhNl80LTAtMS0xLTQ0_bd140200-a030-47d1-90b4-f9e115ad38a7">1.500% Senior Notes due 2023</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="iacaeb3ad67e84bcab6f0ff402ffc8bdb_D20210430-20210430"
      id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl8xL2ZyYWc6OGE0MTU3ZTViN2M5NDcxNmIyNjJhODFjOTE4Y2IzNDIvdGFibGU6NWVmYmU4OTVmZDFmNDc4NTk3ODBjYmZjMjVlMTJkYTYvdGFibGVyYW5nZTo1ZWZiZTg5NWZkMWY0Nzg1OTc4MGNiZmMyNWUxMmRhNl80LTItMS0xLTQ4_6ad89589-d71b-421b-978e-cedf93db307f">ABBV23B</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="iacaeb3ad67e84bcab6f0ff402ffc8bdb_D20210430-20210430"
      id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl8xL2ZyYWc6OGE0MTU3ZTViN2M5NDcxNmIyNjJhODFjOTE4Y2IzNDIvdGFibGU6NWVmYmU4OTVmZDFmNDc4NTk3ODBjYmZjMjVlMTJkYTYvdGFibGVyYW5nZTo1ZWZiZTg5NWZkMWY0Nzg1OTc4MGNiZmMyNWUxMmRhNl80LTQtMS0xLTUy_aa48a20e-5ce3-43bc-bce2-cc05958f70c9">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i87f971760f124ed79664442df3b25e34_D20210430-20210430"
      id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl8xL2ZyYWc6OGE0MTU3ZTViN2M5NDcxNmIyNjJhODFjOTE4Y2IzNDIvdGFibGU6NWVmYmU4OTVmZDFmNDc4NTk3ODBjYmZjMjVlMTJkYTYvdGFibGVyYW5nZTo1ZWZiZTg5NWZkMWY0Nzg1OTc4MGNiZmMyNWUxMmRhNl8zLTAtMS0xLTA_cbd80326-8a9d-482c-a6ab-5598139d8c20">1.375% Senior Notes due 2024</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i87f971760f124ed79664442df3b25e34_D20210430-20210430"
      id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl8xL2ZyYWc6OGE0MTU3ZTViN2M5NDcxNmIyNjJhODFjOTE4Y2IzNDIvdGFibGU6NWVmYmU4OTVmZDFmNDc4NTk3ODBjYmZjMjVlMTJkYTYvdGFibGVyYW5nZTo1ZWZiZTg5NWZkMWY0Nzg1OTc4MGNiZmMyNWUxMmRhNl8zLTItMS0xLTA_9e2a841f-c4c2-42ce-aedc-71dcc3c1844c">ABBV24</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i87f971760f124ed79664442df3b25e34_D20210430-20210430"
      id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl8xL2ZyYWc6OGE0MTU3ZTViN2M5NDcxNmIyNjJhODFjOTE4Y2IzNDIvdGFibGU6NWVmYmU4OTVmZDFmNDc4NTk3ODBjYmZjMjVlMTJkYTYvdGFibGVyYW5nZTo1ZWZiZTg5NWZkMWY0Nzg1OTc4MGNiZmMyNWUxMmRhNl8zLTQtMS0xLTA_a9ebb888-2e48-4806-bb5f-006ab0ef6b85">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="ib272ba06fa0d4b20b8126cadf25c8d44_D20210430-20210430"
      id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl8xL2ZyYWc6OGE0MTU3ZTViN2M5NDcxNmIyNjJhODFjOTE4Y2IzNDIvdGFibGU6NWVmYmU4OTVmZDFmNDc4NTk3ODBjYmZjMjVlMTJkYTYvdGFibGVyYW5nZTo1ZWZiZTg5NWZkMWY0Nzg1OTc4MGNiZmMyNWUxMmRhNl82LTAtMS0xLTU0_e64fc861-0ea2-4d1b-ac19-c062a0b196cc">1.250% Senior Notes due 2024</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ib272ba06fa0d4b20b8126cadf25c8d44_D20210430-20210430"
      id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl8xL2ZyYWc6OGE0MTU3ZTViN2M5NDcxNmIyNjJhODFjOTE4Y2IzNDIvdGFibGU6NWVmYmU4OTVmZDFmNDc4NTk3ODBjYmZjMjVlMTJkYTYvdGFibGVyYW5nZTo1ZWZiZTg5NWZkMWY0Nzg1OTc4MGNiZmMyNWUxMmRhNl82LTItMS0xLTU4_28c15be2-c9ac-4306-8976-be9d1f22765d">ABBV24B</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ib272ba06fa0d4b20b8126cadf25c8d44_D20210430-20210430"
      id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl8xL2ZyYWc6OGE0MTU3ZTViN2M5NDcxNmIyNjJhODFjOTE4Y2IzNDIvdGFibGU6NWVmYmU4OTVmZDFmNDc4NTk3ODBjYmZjMjVlMTJkYTYvdGFibGVyYW5nZTo1ZWZiZTg5NWZkMWY0Nzg1OTc4MGNiZmMyNWUxMmRhNl82LTQtMS0xLTYw_9fadb21d-7047-4828-b465-848c9c24e5c2">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="ia74871cf5e6446fe98daf5c758cc9155_D20210430-20210430"
      id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl8xL2ZyYWc6OGE0MTU3ZTViN2M5NDcxNmIyNjJhODFjOTE4Y2IzNDIvdGFibGU6NWVmYmU4OTVmZDFmNDc4NTk3ODBjYmZjMjVlMTJkYTYvdGFibGVyYW5nZTo1ZWZiZTg5NWZkMWY0Nzg1OTc4MGNiZmMyNWUxMmRhNl80LTAtMS0xLTA_54019f8d-507c-4bc8-ba2b-f5a12e68e646">0.750% Senior Notes due 2027</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ia74871cf5e6446fe98daf5c758cc9155_D20210430-20210430"
      id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl8xL2ZyYWc6OGE0MTU3ZTViN2M5NDcxNmIyNjJhODFjOTE4Y2IzNDIvdGFibGU6NWVmYmU4OTVmZDFmNDc4NTk3ODBjYmZjMjVlMTJkYTYvdGFibGVyYW5nZTo1ZWZiZTg5NWZkMWY0Nzg1OTc4MGNiZmMyNWUxMmRhNl80LTItMS0xLTA_3e7a3912-8b60-41cf-a01d-688e1ab23e56">ABBV27</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ia74871cf5e6446fe98daf5c758cc9155_D20210430-20210430"
      id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl8xL2ZyYWc6OGE0MTU3ZTViN2M5NDcxNmIyNjJhODFjOTE4Y2IzNDIvdGFibGU6NWVmYmU4OTVmZDFmNDc4NTk3ODBjYmZjMjVlMTJkYTYvdGFibGVyYW5nZTo1ZWZiZTg5NWZkMWY0Nzg1OTc4MGNiZmMyNWUxMmRhNl80LTQtMS0xLTA_26a4fecc-9039-4427-a9ce-6d21e493553c">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="ib7c02690c2a54e689107d2d34c8a565d_D20210430-20210430"
      id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl8xL2ZyYWc6OGE0MTU3ZTViN2M5NDcxNmIyNjJhODFjOTE4Y2IzNDIvdGFibGU6NWVmYmU4OTVmZDFmNDc4NTk3ODBjYmZjMjVlMTJkYTYvdGFibGVyYW5nZTo1ZWZiZTg5NWZkMWY0Nzg1OTc4MGNiZmMyNWUxMmRhNl81LTAtMS0xLTA_dc1a7d1f-c2c0-4f75-8260-605e4123f2b2">2.125% Senior Notes due 2028</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ib7c02690c2a54e689107d2d34c8a565d_D20210430-20210430"
      id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl8xL2ZyYWc6OGE0MTU3ZTViN2M5NDcxNmIyNjJhODFjOTE4Y2IzNDIvdGFibGU6NWVmYmU4OTVmZDFmNDc4NTk3ODBjYmZjMjVlMTJkYTYvdGFibGVyYW5nZTo1ZWZiZTg5NWZkMWY0Nzg1OTc4MGNiZmMyNWUxMmRhNl81LTItMS0xLTA_96fa1d08-5e44-41b6-b1b3-50408f008264">ABBV28</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ib7c02690c2a54e689107d2d34c8a565d_D20210430-20210430"
      id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl8xL2ZyYWc6OGE0MTU3ZTViN2M5NDcxNmIyNjJhODFjOTE4Y2IzNDIvdGFibGU6NWVmYmU4OTVmZDFmNDc4NTk3ODBjYmZjMjVlMTJkYTYvdGFibGVyYW5nZTo1ZWZiZTg5NWZkMWY0Nzg1OTc4MGNiZmMyNWUxMmRhNl81LTQtMS0xLTA_a3f88292-0c72-4f03-af15-f5b7f9c4c87a">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i29032be1176d413e92e42e8adbbab24d_D20210430-20210430"
      id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl8xL2ZyYWc6OGE0MTU3ZTViN2M5NDcxNmIyNjJhODFjOTE4Y2IzNDIvdGFibGU6NWVmYmU4OTVmZDFmNDc4NTk3ODBjYmZjMjVlMTJkYTYvdGFibGVyYW5nZTo1ZWZiZTg5NWZkMWY0Nzg1OTc4MGNiZmMyNWUxMmRhNl85LTAtMS0xLTYy_eecb898a-973f-49cb-932e-60df2c578612">2.625% Senior Notes due 2028</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i29032be1176d413e92e42e8adbbab24d_D20210430-20210430"
      id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl8xL2ZyYWc6OGE0MTU3ZTViN2M5NDcxNmIyNjJhODFjOTE4Y2IzNDIvdGFibGU6NWVmYmU4OTVmZDFmNDc4NTk3ODBjYmZjMjVlMTJkYTYvdGFibGVyYW5nZTo1ZWZiZTg5NWZkMWY0Nzg1OTc4MGNiZmMyNWUxMmRhNl85LTItMS0xLTY1_16e686b6-3b28-47ae-a948-81d889266c2e">ABBV28B</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i29032be1176d413e92e42e8adbbab24d_D20210430-20210430"
      id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl8xL2ZyYWc6OGE0MTU3ZTViN2M5NDcxNmIyNjJhODFjOTE4Y2IzNDIvdGFibGU6NWVmYmU4OTVmZDFmNDc4NTk3ODBjYmZjMjVlMTJkYTYvdGFibGVyYW5nZTo1ZWZiZTg5NWZkMWY0Nzg1OTc4MGNiZmMyNWUxMmRhNl85LTQtMS0xLTcw_1cda4753-645d-49c2-959c-45ff3e070e6e">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="ifc45b489215749e7960282bf6274a10f_D20210430-20210430"
      id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl8xL2ZyYWc6OGE0MTU3ZTViN2M5NDcxNmIyNjJhODFjOTE4Y2IzNDIvdGFibGU6NWVmYmU4OTVmZDFmNDc4NTk3ODBjYmZjMjVlMTJkYTYvdGFibGVyYW5nZTo1ZWZiZTg5NWZkMWY0Nzg1OTc4MGNiZmMyNWUxMmRhNl8xMC0wLTEtMS02NA_9bd670d8-c852-4611-9b5b-2167fd91dfe5">2.125% Senior Notes due 2029</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ifc45b489215749e7960282bf6274a10f_D20210430-20210430"
      id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl8xL2ZyYWc6OGE0MTU3ZTViN2M5NDcxNmIyNjJhODFjOTE4Y2IzNDIvdGFibGU6NWVmYmU4OTVmZDFmNDc4NTk3ODBjYmZjMjVlMTJkYTYvdGFibGVyYW5nZTo1ZWZiZTg5NWZkMWY0Nzg1OTc4MGNiZmMyNWUxMmRhNl8xMC0yLTEtMS02OA_93cb9a5c-e223-4008-b7c3-cc4c9e996e87">ABBV29</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ifc45b489215749e7960282bf6274a10f_D20210430-20210430"
      id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl8xL2ZyYWc6OGE0MTU3ZTViN2M5NDcxNmIyNjJhODFjOTE4Y2IzNDIvdGFibGU6NWVmYmU4OTVmZDFmNDc4NTk3ODBjYmZjMjVlMTJkYTYvdGFibGVyYW5nZTo1ZWZiZTg5NWZkMWY0Nzg1OTc4MGNiZmMyNWUxMmRhNl8xMC00LTEtMS03Mg_a5686c1c-c958-4c7e-ba04-c8d8c49568da">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i8ed7fd5ee92346588519bb73fa7ddd03_D20210430-20210430"
      id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl8xL2ZyYWc6OGE0MTU3ZTViN2M5NDcxNmIyNjJhODFjOTE4Y2IzNDIvdGFibGU6NWVmYmU4OTVmZDFmNDc4NTk3ODBjYmZjMjVlMTJkYTYvdGFibGVyYW5nZTo1ZWZiZTg5NWZkMWY0Nzg1OTc4MGNiZmMyNWUxMmRhNl82LTAtMS0xLTA_a420dca9-1756-4f87-b03f-78b8626f9cc3">1.250% Senior Notes due 2031</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i8ed7fd5ee92346588519bb73fa7ddd03_D20210430-20210430"
      id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl8xL2ZyYWc6OGE0MTU3ZTViN2M5NDcxNmIyNjJhODFjOTE4Y2IzNDIvdGFibGU6NWVmYmU4OTVmZDFmNDc4NTk3ODBjYmZjMjVlMTJkYTYvdGFibGVyYW5nZTo1ZWZiZTg5NWZkMWY0Nzg1OTc4MGNiZmMyNWUxMmRhNl82LTItMS0xLTA_3466121f-047f-4512-9b4e-b5749b3c4023">ABBV31</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i8ed7fd5ee92346588519bb73fa7ddd03_D20210430-20210430"
      id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl8xL2ZyYWc6OGE0MTU3ZTViN2M5NDcxNmIyNjJhODFjOTE4Y2IzNDIvdGFibGU6NWVmYmU4OTVmZDFmNDc4NTk3ODBjYmZjMjVlMTJkYTYvdGFibGVyYW5nZTo1ZWZiZTg5NWZkMWY0Nzg1OTc4MGNiZmMyNWUxMmRhNl82LTQtMS0xLTA_154251b1-6752-4f66-a24b-f9831e1e8f98">NYSE</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="i372845ab48f94e268be1959a2195352e_D20210430-20210430"
      id="id3VybDovL2RvY3MudjEvZG9jOjhhZWI3MDBiYThkMzQzMmJiMTg4Y2IxNjFjMWRhMTRmL3NlYzo4YWViNzAwYmE4ZDM0MzJiYjE4OGNiMTYxYzFkYTE0Zl8xL2ZyYWc6OGE0MTU3ZTViN2M5NDcxNmIyNjJhODFjOTE4Y2IzNDIvdGV4dHJlZ2lvbjo4YTQxNTdlNWI3Yzk0NzE2YjI2MmE4MWM5MThjYjM0Ml8xODQ3_34950660-e2f6-431d-ad2e-bbcc431ee5cf">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140409185164888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information Document<br></strong></div></th>
<th class="th"><div>Apr. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Apr. 30,  2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ABBVIE INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001551152<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-35565<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">32-0375147<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1 North Waukegan Road<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">North Chicago<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">IL<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">60064-6400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">847<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">932-7900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock | NEW YORK STOCK EXCHANGE, INC.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.01 Par Value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ABBV<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock | CHICAGO STOCK EXCHANGE, INC</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.01 Par Value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ABBV<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">CHX<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=abbv_Sec0500SeniorNotesDue2021Member', window );">Sec 0.500 Senior Notes Due 2021 | NEW YORK STOCK EXCHANGE, INC.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">0.500% Senior Notes due 2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ABBV21C<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=abbv_Sec1500SeniorNotesDue2023Member', window );">Sec 1.500 Senior Notes Due 2023 | NEW YORK STOCK EXCHANGE, INC.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.500% Senior Notes due 2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ABBV23B<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=abbv_Sec1.375SeniorNotesDue2024Member', window );">Sec 1.375 Senior Notes Due 2024 | NEW YORK STOCK EXCHANGE, INC.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.375% Senior Notes due 2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ABBV24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=abbv_Sec1250SeniorNotesDue2024Member', window );">Sec 1.250 Senior Notes Due 2024 | NEW YORK STOCK EXCHANGE, INC.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.250% Senior Notes due 2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ABBV24B<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=abbv_Sec0.750SeniorNotesDue2027Member', window );">Sec 0.750 Senior Notes Due 2027 | NEW YORK STOCK EXCHANGE, INC.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">0.750% Senior Notes due 2027<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ABBV27<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=abbv_Sec2.125SeniorNotesdue2028Member', window );">Sec 2.125 Senior Notes due 2028 | NEW YORK STOCK EXCHANGE, INC.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">2.125% Senior Notes due 2028<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ABBV28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=abbv_Sec2625SeniorNotesDue2028Member', window );">Sec 2.625 Senior Notes Due 2028 | NEW YORK STOCK EXCHANGE, INC.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">2.625% Senior Notes due 2028<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ABBV28B<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=abbv_Sec2125SeniorNotesDue2029Member', window );">Sec 2.125 Senior Notes Due 2029 | NEW YORK STOCK EXCHANGE, INC.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">2.125% Senior Notes due 2029<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ABBV29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=abbv_Sec1.250SeniorNotesdue2031Member', window );">Sec 1.250 Senior Notes due 2031 | NEW YORK STOCK EXCHANGE, INC.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.250% Senior Notes due 2031<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ABBV31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingsExchangeAxis=exch_XNYS">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingsExchangeAxis=exch_XNYS</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingsExchangeAxis=exch_XCHI">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingsExchangeAxis=exch_XCHI</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=abbv_Sec0500SeniorNotesDue2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=abbv_Sec0500SeniorNotesDue2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=abbv_Sec1500SeniorNotesDue2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=abbv_Sec1500SeniorNotesDue2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=abbv_Sec1.375SeniorNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=abbv_Sec1.375SeniorNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=abbv_Sec1250SeniorNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=abbv_Sec1250SeniorNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=abbv_Sec0.750SeniorNotesDue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=abbv_Sec0.750SeniorNotesDue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=abbv_Sec2.125SeniorNotesdue2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=abbv_Sec2.125SeniorNotesdue2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=abbv_Sec2625SeniorNotesDue2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=abbv_Sec2625SeniorNotesDue2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=abbv_Sec2125SeniorNotesDue2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=abbv_Sec2125SeniorNotesDue2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=abbv_Sec1.250SeniorNotesdue2031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=abbv_Sec1.250SeniorNotesdue2031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( )L]GE('04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " ";/9Y2(=/)]NX    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+/
M2L0P$(=?17)O)_VC0NCFHGA2$%Q0O(5D=C?8-"$9:??M3>MN%]$'\)B97[[Y
M!J;306@?\3GZ@)$LIJO)]4,2.FS8@2@(@*0/Z%0J<V+(S9V/3E%^QCT$I3_4
M'J'F_ 8<DC**%,S (JQ$)CNCA8ZHR,<3WN@5'SYCO\",!NS1X4 )JK(")N>)
MX3CU'5P ,XPPNO1=0+,2E^J?V*4#[)2<DEU3XSB68[/D\@X5O#T]OBSK%G9(
MI :-^5>R@HX!-^P\^;6YN]\^,%GSNBIX6S1\RV]%VXKKZGUV_>%W$7;>V)W]
MQ\9G0=G!K[N07U!+ P04    " ";/9Y2F5R<(Q &  "<)P  $P   'AL+W1H
M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.
M'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X
M8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#W(*+"$MX%,O6
M7.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+5(UEHP$3
M5T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4PL3 :F<_5FO'
MT=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q>#BVR]*+
M<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*C5M/TVMW
MW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6UY4#3( !8
M<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0!0X -\31
M3%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_
M::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="?,_V]I&E
M)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>41B1%G\@M
MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7
MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V<
M/!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,CIW0FS>@S
M&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV
M&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYBSHN0
M$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'
MHYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y
M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'5*^3*=@Y
MG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+5--E-XH2
MGD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JVE+ZU)CA*
M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*
MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#
MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B
M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P
MOFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V$I<8O./F
MQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W
MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2
MD 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4BK ,!2$7
M<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4S;L:OB9@
M2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F
M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+
M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5
M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0    (
M )L]GE(#<QF8Q@8   0L   8    >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
MM9I?;]I(%,6?NY]BA':E72D!>\9_2)5$2@AM4%J"0K9I=[4/CCV %=O#CH<F
MD?;#[]@0+DW-'5J;EP0#<WQ\[_%OQL;'CT(^Y#/.%7E*DRP_:<V4FK_M=/)P
MQM,@;XLYS_0G$R'30.E-.>WD<\F#J!R4)AUJ65XG#>*L=7I<OC>2I\=BH9(X
MXR-)\D6:!O+YG"?B\:1EMU[>N(FG,U6\T3D]G@=3/N;JS_E(ZJW.6B6*4Y[E
ML<B(Y).3UIG]]MSWB@'E-S[%_#'?>$V*0[D7XJ'8&$0G+:MPQ!,>JD(BT/^^
M\AY/DD))^_AW)=I:[[,8N/GZ1?U=>?#Z8.Z#G/=$<A=':G;2ZK9(Q"?!(E$W
MXO&2KP[(+?1"D>3E7_*X_*[GM$BXR)5(5X.U@S3.EO^#IU4A-@8P:\L NAI
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MY>K'(&BTMK%4QPE=!%Y/EF,EP@?R'QGV[\B7ZYLK,KZ][EV1_N?>Y=GP??_
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M\N6,!Q&7Q1?TYQ.A.[+:*)X<73_X>_H_4$L#!!0    ( )L]GE*?H!OPL0(
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M-4H2U\7!ZQ^4ZD2HN7/08&<B+EA0BJN$7/D=<.I[.T!*1D.QD8E>I6.5Z*U
M.EK >MKBRAE#VQH%.JB]XY8:8P*IL0,@9^O1=#%-)IXPC,^[V?S!9@K(RDT*
M$3FQ!'_'G2/)W55D(TADIJ]X(;+U[/M!3EN#OI'-X_T,:3?D@6)8YL_X>\87
M_QO.\1'"[K\_L;S63AI_YHOA/UY_ 5!+ 0(4 Q0    ( )L]GE('04UB@0
M +$    0              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#
M%     @ FSV>4B'3R?;N    *P(  !$              ( !KP   &1O8U!R
M;W!S+V-O<F4N>&UL4$L! A0#%     @ FSV>4IE<G",0!@  G"<  !,
M         ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " ";
M/9Y2 W,9F,8&   $+   &               @($-"   >&PO=V]R:W-H965T
M<R]S:&5E=#$N>&UL4$L! A0#%     @ FSV>4I^@&_"Q @  X@P   T
M         ( !"0\  'AL+W-T>6QE<RYX;6Q02P$"% ,4    " ";/9Y2EXJ[
M',     3 @  "P              @ 'E$0  7W)E;',O+G)E;'-02P$"% ,4
M    " ";/9Y2'#AEZC\!   \ @  #P              @ '.$@  >&PO=V]R
M:V)O;VLN>&UL4$L! A0#%     @ FSV>4B0>FZ*M    ^ $  !H
M     ( !.A0  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%
M  @ FSV>4F60>9(9 0  SP,  !,              ( !'Q4  %M#;VYT96YT
A7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  :18

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>12</ContextCount>
  <ElementCount>96</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>12</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="abbv-20210430.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Document and Entity Information Document</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/DocumentandEntityInformationDocument</Role>
      <ShortName>Document and Entity Information Document</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="abbv-20210430.htm">abbv-20210430.htm</File>
    <File>abbv-20210331xexhibit991.htm</File>
    <File>abbv-20210430.xsd</File>
    <File>abbv-20210430_cal.xml</File>
    <File>abbv-20210430_def.xml</File>
    <File>abbv-20210430_lab.xml</File>
    <File>abbv-20210430_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/exch/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "abbv-20210430.htm": {
   "axisCustom": 0,
   "axisStandard": 2,
   "contextCount": 12,
   "dts": {
    "calculationLink": {
     "local": [
      "abbv-20210430_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "abbv-20210430_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "abbv-20210430.htm"
     ]
    },
    "labelLink": {
     "local": [
      "abbv-20210430_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "abbv-20210430_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "abbv-20210430.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 41,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2020-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 96,
   "memberCustom": 9,
   "memberStandard": 3,
   "nsprefix": "abbv",
   "nsuri": "http://www.abbvie.com/20210430",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20210430.htm",
      "contextRef": "i372845ab48f94e268be1959a2195352e_D20210430-20210430",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Document and Entity Information Document",
     "role": "http://www.abbvie.com/role/DocumentandEntityInformationDocument",
     "shortName": "Document and Entity Information Document",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abbv-20210430.htm",
      "contextRef": "i372845ab48f94e268be1959a2195352e_D20210430-20210430",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 12,
   "tag": {
    "abbv_Sec0.750SeniorNotesDue2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sec 0.750 Senior Notes Due 2027 [Member]",
        "label": "Sec 0.750 Senior Notes Due 2027 [Member]",
        "terseLabel": "Sec 0.750 Senior Notes Due 2027"
       }
      }
     },
     "localname": "Sec0.750SeniorNotesDue2027Member",
     "nsuri": "http://www.abbvie.com/20210430",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_Sec0500SeniorNotesDue2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sec 0.500 Senior Notes Due 2021",
        "label": "Sec 0.500 Senior Notes Due 2021 [Member]",
        "terseLabel": "Sec 0.500 Senior Notes Due 2021"
       }
      }
     },
     "localname": "Sec0500SeniorNotesDue2021Member",
     "nsuri": "http://www.abbvie.com/20210430",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_Sec1.250SeniorNotesdue2031Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sec 1.250 Senior Notes due 2031 [Member]",
        "label": "Sec 1.250 Senior Notes due 2031 [Member]",
        "terseLabel": "Sec 1.250 Senior Notes due 2031"
       }
      }
     },
     "localname": "Sec1.250SeniorNotesdue2031Member",
     "nsuri": "http://www.abbvie.com/20210430",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_Sec1.375SeniorNotesDue2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sec 1.375 Senior Notes Due 2024 [Member]",
        "label": "Sec 1.375 Senior Notes Due 2024 [Member]",
        "terseLabel": "Sec 1.375 Senior Notes Due 2024"
       }
      }
     },
     "localname": "Sec1.375SeniorNotesDue2024Member",
     "nsuri": "http://www.abbvie.com/20210430",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_Sec1250SeniorNotesDue2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sec 1.250 Senior Notes Due 2024",
        "label": "Sec 1.250 Senior Notes Due 2024 [Member]",
        "terseLabel": "Sec 1.250 Senior Notes Due 2024"
       }
      }
     },
     "localname": "Sec1250SeniorNotesDue2024Member",
     "nsuri": "http://www.abbvie.com/20210430",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_Sec1500SeniorNotesDue2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sec 1.500 Senior Notes Due 2023",
        "label": "Sec 1.500 Senior Notes Due 2023 [Member]",
        "terseLabel": "Sec 1.500 Senior Notes Due 2023"
       }
      }
     },
     "localname": "Sec1500SeniorNotesDue2023Member",
     "nsuri": "http://www.abbvie.com/20210430",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_Sec2.125SeniorNotesdue2028Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sec 2.125 Senior Notes due 2028 [Member]",
        "label": "Sec 2.125 Senior Notes due 2028 [Member]",
        "terseLabel": "Sec 2.125 Senior Notes due 2028"
       }
      }
     },
     "localname": "Sec2.125SeniorNotesdue2028Member",
     "nsuri": "http://www.abbvie.com/20210430",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_Sec2125SeniorNotesDue2029Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sec 2.125 Senior Notes Due 2029",
        "label": "Sec 2.125 Senior Notes Due 2029 [Member]",
        "terseLabel": "Sec 2.125 Senior Notes Due 2029"
       }
      }
     },
     "localname": "Sec2125SeniorNotesDue2029Member",
     "nsuri": "http://www.abbvie.com/20210430",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "domainItemType"
    },
    "abbv_Sec2625SeniorNotesDue2028Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sec 2.625 Senior Notes Due 2028",
        "label": "Sec 2.625 Senior Notes Due 2028 [Member]",
        "terseLabel": "Sec 2.625 Senior Notes Due 2028"
       }
      }
     },
     "localname": "Sec2625SeniorNotesDue2028Member",
     "nsuri": "http://www.abbvie.com/20210430",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntitiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance",
        "label": "Entities [Table]",
        "terseLabel": "Entities [Table]"
       }
      }
     },
     "localname": "EntitiesTable",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Entity Information [Line Items]",
        "terseLabel": "Entity Information [Line Items]"
       }
      }
     },
     "localname": "EntityInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityListingsExchangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.",
        "label": "Entity Listings, Exchange [Axis]",
        "terseLabel": "Entity Listings, Exchange [Axis]"
       }
      }
     },
     "localname": "EntityListingsExchangeAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_ExchangeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383.",
        "label": "Exchange [Domain]",
        "terseLabel": "Exchange [Domain]"
       }
      }
     },
     "localname": "ExchangeDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "exch_XCHI": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CHICAGO STOCK EXCHANGE, INC [Member]",
        "terseLabel": "CHICAGO STOCK EXCHANGE, INC"
       }
      }
     },
     "localname": "XCHI",
     "nsuri": "http://xbrl.sec.gov/exch/2020-01-31",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "domainItemType"
    },
    "exch_XNYS": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NEW YORK STOCK EXCHANGE, INC. [Member]",
        "terseLabel": "NEW YORK STOCK EXCHANGE, INC."
       }
      }
     },
     "localname": "XNYS",
     "nsuri": "http://xbrl.sec.gov/exch/2020-01-31",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001551152-21-000013-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001551152-21-000013-xbrl.zip
M4$L#!!0    ( )L]GE)KHBNF$D(  (V<!  <    86)B=BTR,#(Q,#,S,7AE
M>&AI8FET.3DQ+FAT;>U]:7/;1K;H]_<K^CF31+Y%PEBX2AE7*;)L:VZ\C.0D
M==^76TV@2?88!!@LDIE?_\[I!DAP 07)X ;T3)4C"5N?M<_6Y_SR?]]\NOKR
M/Y^OR3B:N.3S[[_^=G-%7C1?O?K3NGKUZLV7-^3]EP^_D9:F&^1+0+V01]SW
MJ/OJU?7'%^3%.(JFYZ]>/3P\: ^6Y@>C5U]N7^&K6J]<WP^9YD3.B]>_X%_@
M7T:=U__GE__;;)(WOAU/F!<1.V T8@Z)0^Z-R)\."[^29C.YZ\J?S@(^&D?$
MU$V#_.D'7_D]E=<C'KGL=?J>7U[)WW]Y)3[RR\!W9J]_<?@]X<X_7_"AW7/H
MP.GVNT/::K>M7K^MZS9E1J?5ZK9T^K\&+/(5W"Z?":.9R_[Y8L*]YICA]\];
M[6ET\<"=:'QNZ/J/+Y;NB]BWJ$E=/O+.;5@+"^#RT/<B6$8 KY4_RK?/OY%[
MQ_Q:^G;;=_W@_ ==_.\"KS2'=,+=V?G/5_#10<!_;H1 F&;( CZ4-X3\;P8+
MA36+7Q\2(.!YEWLL!<HP$1*2?I]/1H2ZT3]?T,'@GC,^H2-FT+9E4.T_T]$+
M$@9V_C6YUN3%9GOZ[6)"@Q$@<.!'D3\Y1_S=LR#B-G437 FTR<LI:MOZ]-N+
M1S'1-9Q6_[LPT=V.B75.D+!$_O3<;$VC%V6MJU-H79]OK^_NR.WU;]>7=]<'
MYI:??C Z^L7.%M$JA)#+P> /SL@MF_I!%)*W/ BCYK]C&H#L257QEGO4LSEU
MX:8P=J,PE[13ZCB@>IHN&T;G%A)$\"7W'!#E\Z;1RR7WTZ$SGH!B0O+9\2!K
M%F\ZYQ'<;A>"HF>:G3FG''(Q%TOX,DRM;2&"-K//&^[&N"%=?[XC_I#\P]#Z
M?>)[A))WEY>?R:\TY.%//[3[%^32^4\<XJVKCYA:OUV<=OF;A:)XR11_PUP.
MF] JR3^R"-3$/?-B%DJ:6V#NZ.17[KI@[*Q2OT&H1VX\M%Q"AO>W#4TGGUF
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M^&T2'7-9 '/?M\?R)[A5N-?"55TX=6M/O(.W XO88SQ1.F&3 0"0"(-\V;O
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MDPHV[*X)Z2[V[6=TQ#R%6P^,JM.AU-Y6JLZ9JCMK>V>USA<_KR'M3BHL3O+
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MDO(9^FW<?'?DY_WHJX7"SD_:J4F+JNMH*,*F<'6D,B^7@0]IKTB[1[UM4 D
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MF3I/M)LD -;\'N[KVQQB"W'6Z+LNT*5QIZ_JS [@GU;1::__/U!+ P04
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M7%9!G 2Z.],_!ZVZS;6A]NHT;ITUO^_K-_ZVNZV-:@G9GVQBQ]MGMP0O38X
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MXNXC_N?X,#I0 H0?OB&OGL]V\0U02P,$%     @ FSV>4G<)[T+?"@  ;54
M !4   !A8F)V+3(P,C$P-#,P7V1E9BYX;6S=G%M3&\D5Q]_]*13V-0U]O[@6
MIQSL3:AX;9?QUF[RHNK+:9BRI*%F!AN^?<X,$@8D6,RTG0@>0!J-^OS[_,YT
MG[[Q\]_.Y[/)9VC:JE[L[[!=NC.!1:Q3M3C>W_GMXR_$[OSMQ;-G/_^%D#_^
M_N'-Y%4=S^:PZ"8'#?@.TN1+U9U,?D_0?IKDIIY/?J^;3]5G3\B+X4L']>E%
M4QV?=!-..;O]:?-<@,F4646\\XS(H!FQ3&42-0/)D^:@W5^/GR=O;(B,$0>)
MXVT"2+ Q$^<\M<IY(3@?"IU5BT_/^U_!MS#!RBW:X>W^SDG7G3[?V_ORY<ON
M>6AFNW5SO,<I%7NKNW>6MY^OW?]%#'<SY]S>\.G5K6VUZ48LENW]\>N;HW@"
M<T^J1=OY1?QJ ,VG[NJ+U]6HO<L/\=:V>MX.WW]31]\->/ZT"I,[[^C?D=5M
MI+]$&">"[9ZW:>?%L\GDTG.^B4T]@P^0)\N7OWTX7%=:+;J]5,WWEO?L^=D,
M%0\E=!>GL+_35O/3&:RNG320[U2_JG(O2O5R?NI+VQNMZ02%-/$L ,&KL.@#
MO*#&3:6/UWQ5%DF0_=FL*ZAXO>RB>NNYKTHZ>*WH FJ'@L@<Y@&:DE)OE'M-
MYTKD;85]D3Z$SQ7LQGJ^-XA;-:Q^D5XONJJ[.%SDNID/3_[JLS_7W)=*^I:6
M2D$'<0\J]YIF#(YJ4?6?OL&WR\)[A875PWD'BP1I9U*E_9U*J(P_B044+IU(
MSDD>C8Y*@,S>T.F#+/356%5D5L<;!F=],UI?<9_Y +/AZC1!-5TK$VL/AQW,
MVVEB&;)U@?#<=U&".Q(R$\08$#)R4$&8]<AI5Y'80MP]KC_OH14,'T[[%STB
M2BA;-L _W:_@$L_CZK5RS4>\=ZIT2$!3(IEAWRF5\<1%'HC WE5['Z.4MD!-
MKMN\J?UK<+UL5K58/IV/?'S[G*,XQ:XNX,!+.BA^9U(W"9K]'5H"Y'MHJAH?
M@?0*TZ]I-B9I:BS12F%>A$D4\0K3)$JUP<JR:((O2/2&\2>#]O$N76?,QC"^
MK.,'.*[:KO&+[JV?HQYMG& F$AXEUBY#KT=X0C$0700&SI1X:#?9WGK"HQVZ
M#IB/!WR ,=?XV2%V?^?_@HNI$IE)BV.@0)DDTG%-K**6B&"8M5YJ&\H1OF7\
MB2 >X])UQF(,XY?8I*2^6?EEYH^G*5H0D#/Q(28,MH1C5LH",1)<YH(;P4NP
MO6%TZYD^WH7K+.7XY_5P$>OFM&Z&VAUUV$D<U&<8;Q<'=8)IRE;QB'J$T(Y(
M$S$G<"D2&3'*.!CN4RB8'MXC9>NYEW;W>C2H\='P2S6#MV>]7Z92V2R4PDP0
ML\ ^'30D" E$2DDC]QX"8\70?[7[1#@_TI'K4/5XJ!_]^6'"!J?*U>5DVU)8
MPK!2'ML>'K1 .8%AM"E'++YB 9+DJ1SA.T0\$=PE7+S.WHQG_S*E!MIV^:>O
M+ILZQZ7Q(1 < YB^JI0XB)A)9,T2**.!T6+<-PAX(LS'NG:=MRW&^P!?OFL^
MUE\64TZE=H$*XC&7P"&?-<0F:0E+&C)H[%]DN1F>-?-/B_4CW;I.VA4C/>00
M[YKW3?VY6D28*JH]=BN2,.DHD8%28D'C6$$S(8/P'&*YC&VSAJ?%?(R#-TRA
MC)HGNR'L?=UV?O:?ZG1(';%YL3XK;'ER5"@K,1)<=,2)Y 7W.DI78K+L;@5/
MB_KCG;N!^:AYL[[->=F 'X1HM 5 (V&661P68-QYUJLQCKMD8Q!"%:!\W>;6
M<WVT S>0'#5!UJ]US]Z?U(O5R$!$F31SGH"-.,ACH(@-6",--'O+14AJP[+=
M-].\;7?KB8YRY :JHZ;$?F^JKH/%03V?GRV6V3]6S0KJ;4@D.H<C>9D9L3%9
M0I6-DFF?:=0%T&XTOO5\Q[MT ^11<V5']:R*Z,3%\:^8#325GTUM<$IB'8C6
M-&'EM$0Y'M6EI*FP6#E;HL-=M[SU>$<Z<P/;43-?[QOH(PTPN1O60ON5^^9=
MSMBN9!R\<^.Q7H)AOY\C[>?C%,G.)Y&#8BGG HSO5K#UK LY=P/S41-CMV0=
MMNT9--?%.0A)0@#"(F8'4D>-&9] A=1E)D-6F!&6)[^FXZGQ'^?H#5$P:HKL
M".(9=C47C(>/53>#*01!E<J*1)D-D0;'=L&G1)PTDL7 E78EGO?;=K>>\BA'
M;J Z:B+L8^/[';Y'%_-0SZ;8FE .1F&50B:26D,PY"S!L-/X%RS-K@#2&T:W
MGN?C7;@!YJBYKE5DO3Z/)WYQ#,,F!Z6<SY%GE-&OHQC@Q&5IB8\J<!"!LR@*
M/J;7;6\]VM$.W;!KI,"<UNLY-,<8<O]HZB_="789IWYQ,>4V,LSQ(XE&83/"
M<807A(]$>^.Y#U';(J.H>R1L/>]2[MV ??QVL K:CSY@?Y%$T"9I013EF M*
MAOV%]89$RIP4&31G)>:U;A@MB/;:$8$? _11CMNTH6]RN=_[>9S5+:3]G:XY
M@Z\7ZT4'Y]WKV9"[[>^T</QU1_6W8S]KR;'WI]-A1KTOZ&#FV_9=/NKJ^.GE
M>84^,<QCYJ Q&03T"7!+'%XA/"JNA-? ^.9][ .9[-LPX%D:N@P%F'7MZLKM
MF/A3105CY)XC&QMBYG& Z^_AZ(+[0%?"KNMY-32+#U(TO75PI&0(K$LJV?3?
M=?3E*_G"S.KOXO ?$PJ<AIQRS(2J$(BT21"O^BF_Q 6 BT;K[](*_*@0N'&:
MZ'\8 =_BY^]!OI[/^SUP*.C7(2>:4N\L93C0"(YIE-&OL#'."."X@VHODF,;
M\OH"X&\K^7%97RD\MVF/\FW!TQW]6:I^S$$5I4>PJ.KF;=U!^^H,^H-<2VU"
M!":HB,3IP'& Z24),:#4X --*E#LYVYR7S\*]A!#6XNUN!<+/LXK;6R3-K'4
M%K/DS-F(@PR+(PU/.;'<)9(I1.ETC#D\F/!]AK:><#$O%CS<<:5M5QBU)DXN
MQ07!@DA1DISZDR?44.*X380K:X+2QC-J'HSX/DO;S[B8'PN>[K@2Q]5Z *ZT
M89KA[+#$KC-V(GUC$QA671D/*>L<0K8/9GR/H>U'7,J+!<]\7'4BNV:#.+,4
MQ["?, H3@Y1M+P['F\Y"?SXE8V#2&-<V!]_3%]]G:>L9E_-CP:,<*W%\%T/P
MFK@TB+-+<3XI QPD8<.V=&8$L2(&PG+D-CH<3G#_4,CW6MIZR.7\6/!HQY4X
MS=?[D94V$2R5SGN"[0O%C"$J3 R%)8QQ9W7.+DK]8,;W&-I^Q*6\6/  QY4V
MMD&;6VJ3WO(,C!$C$_3: K$6&QO/L7&1@7N>\H,)WV-H^PF7\F+!(QM?D\&;
MJ<+0P(C5F$[%:*E7@@00_0$R'HA/4F'XL<P$< :W]_O>EU3?8VGK&9?SXW<Y
MK?&F:OL-;^UJV768SQ-1RR@H)4992:0 @^E!/T/%\0]H:8TJ=S1GDX+M7-XH
MZ-72_P)AJ6,9SP]1<O>:QK=SOF']QRY?E&12%W5HZ7]C<E-1CHF%Q"0QC.&
M+AE)K(F LHS.T6=J;T]L_=^BO6-9XL>0_18_%B0*J&+ZQ]M_'TVC8L)2)PDH
MC0U1O[\IN#XKL$Y&CUD>!/D D'V!RX4'?'4;Y96Y'[RM9(2OZS&.*KB0<"G@
MX)^'F))[[I*,)'F#64*_8=P:CF-L)D*0V5#K'G)L_2&DT-R6DOI61]WY3/V\
M=ZOB;_#MBV?+R_VO_I]NOGCV7U!+ P04    " ";/9Y2I:NL1\D1  !2L0
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MMV:=^K\9&S2M,F=!FBF=V>2BPK"']U?I^6R76]S81V?$&,6)(L!$=E# (46
M(QQ;MVI8@K2VN@@7CWHL>&K>\R&ARI5SXWH)JV:_V >!$_M -^.=&5IGZ6,(
MLK)*%F:NM#R_3;]<V$>LN2',/^14A0"B;0;U]Y*X48A99\2.A+6_]R?<J^5Z
MOO[^9KY:VW1_]>J;_&C_./K%M_EJ1D.DC+9I=HSB&&!+12!"'.6?&)14$HZ<
M IKF;J9&QHVFP4[5GX*=LL&'7%W'L;@%VG:V#@/8B;G;&2LO.K=#T8/<#<)'
MHWJ[@?O$=VCMYP9V0SHZCVAY3,?;P-&.[I$B6H"$A A@K#E@FA(@XR0A"9&)
MU,@GO6GL;6I.(0\L"X4K TOL%Y\WX^R6X R&W@@93@-P'3.<9@3]4IS!D!PQ
MQ^F%J'>RXX106[;3+&34=,?)GN-\Q^TA__CKTOKR%YGFEZG2,Q%QR!6%($1"
M \RA!%P3#HAFDC L$HT3UXAK7_#4W&FN6Y K%^3:N4=4!V"UQU!=(3BQ3W2T
MWBM&JC*U1U1T(&ZT.*C*B/W(I_+W_I1[8;VTRCWU+PM^.XN)XBBB!D22*X )
MLUF.Q-QF.3**!)7(,M*5<P>2IT:Z!^6"7#MWTAW"U<ZZSB"<F':.]GO1KM+6
M'KP[E#<:\2K-V&=>=8.NLPTOE+)_V-6U#97TV^Q=EGZ96Q5GG":4\WQ^SS#+
MOU@F0#"#@( LYCK6L8':;[ZANJ.I$7.;16^5_2DHU+60!CN%?:<<:O!UG73H
MC]HXTPX= .LP[]",1N^9AQKQ(\\]-!M9GGUH:>_O&*[3Q5S.\QF-WZW(;,[M
MBRI#'.'8 !/%=F!FR #&*0<0VIA<&0XU<0Z&R^*GY@0>-0QV*KK3O@*]=K+W
MP^34\P8><'B1NM[J'E2N$#H:@>L-VJ=M0ZONBW0/52\OK<P9@Y(0RAB(L4H
MUD0##JD B&@BD)2:<N:[6G?0P]0H^[!RM=$RL&H&N9[^*WB'0+93MS<\)V:O
M-S*=EO<JK1]@G>]0[N@+?I5F5:W\53?L&I3?\&^OE94Z-_--6>K5Y\ULJE!0
MQS$!8:(PP(@(.PQ'$+ 81:%4"!H:^T7E-3U-C=[;*--J&QRJ&VST]8W*ZP!V
M#<L'@&V<N-P?L0YA>0L:O>/R.ODC!^8M9I8C\[8'_-S#YQ6XY?Q^=IG>W:7+
MZW4J/VT766*5$$02#2(CB4W6;<;.I(E!S!C#B<W4XS!R<0NU/4S-'6P4# H-
MW:A?#UXSY0>!Y-1SV'MH#+CDU&KZ025Q8;;A*U'HO7UVPVV]6*]VWQR3O+Z3
M4<C=:N..U.T-_<?Z=YG.Q6FK85$\E%<^9V^-L2^EB41$I;+Y-@XEP)+G^;:1
MP' 1B9 *S)1Q'>CKNYD:K:VF0.ZI&FQT#0IEW8?X!ES;Q_=AT#HQX[L!Y36R
MM^/08UAO$#[:F-YNX/Z [M"Z8[ _UZL;+A9ZIJE.0DD3H"(H\ST+(6!8*R"(
M8%&BN0QIZ!7<[R1/C>8[Y8(/A7J^57P/@#D&ZUU@&",X=T' /Q@_MK9O\/T@
M;]Q@^]B,4G!=:M"MS@X2"$N5)&@;&G)%J6%( 1WENX@2R(!@) (1%DPQHT6<
M0)\RNZ;.ID;2O+0)GEN%*TN;D%^-6"/*S30>&KM3SY4WP]:QQJX1/[\2NZ%P
M'+'"KLMKZ%U8YX)+6UU=HXQ1R^I<K#FNJG-ZINN,YNNE3+/[-"M>EV*I\C+]
MO%QGWXORL="^!QS+"" 2"AOZ, :8C8: 880)Q!$6RGESD4-_4_.UV[FZ YWW
M5M*WFGO6Y[G@[CK=.1B:XTQZ]@*RP_RG$SR]9T&;>QEY+M3)Y/*,J-MC'9S,
M=N?%R_2.SY<S2A*!$AP"P04'&#,#$AUBP Q,=!QS2I33A&A9].1<Q\,FGXU^
M/LG4(68.OJ S$J>FO3,(?N2NM+</CP\%CD?92D,.V%G=HN/>I:I (MI&JS*4
M6$.(063R?<0FDH CQ4$2(<*4#:GL>.^U=:FALZF1=;-=I"Z8C3SWW32A[)93
M#87="#E5 VQ=]RTUX>>Y;6D@'$?=M>3_&OIO5G+ I76O4I.,<;<J.5A3VJGD
M\DS'9> %7ZW>FF(I:CN$AZ& (:8(:$)9OF4IGSPV$> 1BXVA2%+F5*59W\74
M/&JA89":W>*G5Q#4@&2S_QP&GQ-[35]H_->%:ZT?=&&XW,NX*\.U5I:6ANM;
M^C%<VV!L]M?5OZ]G6"E!$1<@84E>QIDHP$-I@R4H.#8<QJ%R"I8>)$Z-OU>O
M_@S^_?;];\'US=O+WX)7?UW^Z\75KZ]^"EY?79Z[L?@1K6;2=L+@Q!QM-'_
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M/A([,J&KC2HSN:9=]PN13)K=%:%?GH2]7NN[U0Q1$9D()@#C_+Q?8@A@1C-
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M!D=^SD(F/F1\"&C$JI[VKCV>LM2+#[TC? RGZ18 PO<1]SO!I"X8NPS&)V6
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MR\%PG\* @Y(G7!EG'?U%<\APTF\%23\5,_AX>;M8HVP62K6S\)&WI;8A04C
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MZK]02P$"% ,4    " ";/9Y2:Z(KIA)"  "-G 0 '               @ $
M    86)B=BTR,#(Q,#,S,7AE>&AI8FET.3DQ+FAT;5!+ 0(4 Q0    ( )L]
MGE*&\Y32XAL  +H" 0 1              "  4Q"  !A8F)V+3(P,C$P-#,P
M+FAT;5!+ 0(4 Q0    ( )L]GE(B@I$5S0,  '\3   1              "
M 5U>  !A8F)V+3(P,C$P-#,P+GAS9%!+ 0(4 Q0    ( )L]GE+Q #$0C0$
M !\#   5              "  5EB  !A8F)V+3(P,C$P-#,P7V-A;"YX;6Q0
M2P$"% ,4    " ";/9Y2=PGO0M\*  !M50  %0              @ $99
M86)B=BTR,#(Q,#0S,%]D968N>&UL4$L! A0#%     @ FSV>4J6KK$?)$0
M4K$  !4              ( !*V\  &%B8G8M,C R,3 T,S!?;&%B+GAM;%!+
M 0(4 Q0    ( )L]GE+EZ-R19PH  *)8   5              "  2>!  !A
J8F)V+3(P,C$P-#,P7W!R92YX;6Q02P4&      < !P#4 0  P8L

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
